<!DOCTYPE html>
<html lang="tr">
<head>
<meta charset="UTF-8">
<meta name="viewport" content="width=device-width, initial-scale=1.0">
<title>Sifiliz â€” GÃ¼ncel Klinik EÄŸitim ModÃ¼lÃ¼</title>
<link href="https://fonts.googleapis.com/css2?family=DM+Mono:ital,wght@0,400;0,500;1,400&family=Fraunces:ital,opsz,wght@0,9..144,300;0,9..144,600;0,9..144,800;1,9..144,300;1,9..144,500&display=swap" rel="stylesheet">
<style>
:root{
  --bg:#0a0e13;--bg2:#0f1520;--bg3:#141c28;
  --card:#111822;--border:#1e2d3d;--border2:#253548;
  --red:#e85c5c;--red-d:rgba(232,92,92,.12);
  --amber:#e8a24a;--amber-d:rgba(232,162,74,.12);
  --teal:#3dd6c8;--teal-d:rgba(61,214,200,.10);
  --green:#4ecb87;--green-d:rgba(78,203,135,.10);
  --blue:#5a9cf5;--blue-d:rgba(90,156,245,.10);
  --purple:#b07ef5;--purple-d:rgba(176,126,245,.10);
  --txt:#c5d5e8;--txt-d:#5c7a95;--txt-m:#8aa5be;--wh:#e8f0f8;
}
*{margin:0;padding:0;box-sizing:border-box}
html{scroll-behavior:smooth}
body{font-family:'Fraunces',Georgia,serif;background:var(--bg);color:var(--txt);min-height:100vh;overflow-x:hidden}
body::after{content:'';position:fixed;inset:0;background-image:url("data:image/svg+xml,%3Csvg viewBox='0 0 256 256' xmlns='http://www.w3.org/2000/svg'%3E%3Cfilter id='n'%3E%3CfeTurbulence type='fractalNoise' baseFrequency='0.9' numOctaves='4' stitchTiles='stitch'/%3E%3C/filter%3E%3Crect width='100%25' height='100%25' filter='url(%23n)' opacity='0.03'/%3E%3C/svg%3E");pointer-events:none;z-index:999}

/* LOGIN */
#loginScreen{position:fixed;inset:0;z-index:100;background:var(--bg);display:flex;align-items:center;justify-content:center;transition:opacity .5s}
.login-wrap{width:min(440px,90vw);text-align:center}
.login-badge{display:inline-block;font-family:'DM Mono',monospace;font-size:10px;letter-spacing:3px;color:var(--teal);border:1px solid rgba(61,214,200,.3);background:var(--teal-d);padding:6px 14px;border-radius:20px;margin-bottom:24px;text-transform:uppercase}
.login-title{font-size:clamp(28px,5vw,44px);font-weight:800;line-height:1.1;color:var(--wh);margin-bottom:8px;letter-spacing:-1px}
.login-title em{font-style:italic;color:var(--teal)}
.login-sub{font-size:13px;color:var(--txt-d);margin-bottom:36px;font-family:'DM Mono',monospace;letter-spacing:.5px}
.login-field{background:var(--card);border:1px solid var(--border2);border-radius:10px;padding:14px 18px;font-family:'DM Mono',monospace;font-size:14px;color:var(--wh);width:100%;outline:none;margin-bottom:12px;transition:border-color .2s}
.login-field:focus{border-color:var(--teal)}
.login-field::placeholder{color:var(--txt-d)}
.btn-login{width:100%;background:linear-gradient(135deg,var(--teal),#2ab0a4);color:#071210;border:none;border-radius:10px;padding:16px;font-family:'Fraunces',serif;font-weight:800;font-size:16px;cursor:pointer;transition:transform .2s,box-shadow .2s}
.btn-login:hover{transform:translateY(-2px);box-shadow:0 12px 32px rgba(61,214,200,.25)}
.login-note{font-size:11px;color:var(--txt-d);margin-top:14px;font-family:'DM Mono',monospace}

/* APP */
#app{display:none;min-height:100vh}
.topbar{position:sticky;top:0;z-index:50;background:rgba(10,14,19,.93);backdrop-filter:blur(12px);border-bottom:1px solid var(--border);padding:0 24px;display:flex;align-items:center;justify-content:space-between;height:56px}
.topbar-brand{font-weight:800;font-size:17px;color:var(--wh);letter-spacing:-.5px}
.topbar-brand span{color:var(--teal)}
.topbar-right{display:flex;align-items:center;gap:12px}
.topbar-user{font-family:'DM Mono',monospace;font-size:12px;color:var(--txt-d)}
.tts-btn{background:var(--teal-d);border:1px solid rgba(61,214,200,.3);color:var(--teal);padding:7px 14px;border-radius:20px;font-family:'DM Mono',monospace;font-size:11px;cursor:pointer;transition:all .2s;letter-spacing:.5px}
.tts-btn.speaking{animation:pulse 1.4s infinite}
@keyframes pulse{0%,100%{box-shadow:0 0 0 0 rgba(61,214,200,.4)}50%{box-shadow:0 0 0 8px rgba(61,214,200,0)}}
.logout-btn{background:none;border:1px solid var(--border2);color:var(--txt-d);padding:7px 14px;border-radius:20px;font-family:'DM Mono',monospace;font-size:11px;cursor:pointer;transition:all .2s}
.logout-btn:hover{border-color:var(--red);color:var(--red)}
.progress-track{height:3px;background:var(--border)}
.progress-fill{height:100%;background:linear-gradient(90deg,var(--teal),var(--blue));transition:width .6s cubic-bezier(.4,0,.2,1)}
.sec-nav{display:flex;overflow-x:auto;gap:4px;padding:10px 24px;border-bottom:1px solid var(--border);scrollbar-width:none}
.sec-nav::-webkit-scrollbar{display:none}
.sec-tab{white-space:nowrap;padding:8px 14px;background:none;border:1px solid transparent;border-radius:8px;font-family:'DM Mono',monospace;font-size:10px;letter-spacing:.5px;color:var(--txt-d);cursor:pointer;transition:all .2s;text-transform:uppercase}
.sec-tab:hover{color:var(--txt);border-color:var(--border2)}
.sec-tab.active{background:var(--teal-d);border-color:rgba(61,214,200,.4);color:var(--teal)}

/* MAIN */
.main{max-width:920px;margin:0 auto;padding:40px 24px 80px}
.sec-page{display:none;animation:fadeUp .45s ease}
.sec-page.active{display:block}
@keyframes fadeUp{from{opacity:0;transform:translateY(18px)}to{opacity:1;transform:translateY(0)}}
.page-tag{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:3px;text-transform:uppercase;color:var(--teal);margin-bottom:12px}
.page-h1{font-size:clamp(26px,4vw,40px);font-weight:800;color:var(--wh);line-height:1.15;letter-spacing:-1px;margin-bottom:10px}
.page-h1 em{font-style:italic;color:var(--amber)}
.page-intro{font-size:15px;color:var(--txt-m);line-height:1.75;max-width:700px;margin-bottom:32px;border-left:2px solid var(--teal);padding-left:16px}
.divider{height:1px;background:var(--border);margin:28px 0}
.section-subtitle{font-size:17px;font-weight:700;color:var(--wh);margin-bottom:16px;display:flex;align-items:center;gap:10px}
.section-subtitle::after{content:'';flex:1;height:1px;background:var(--border)}

/* CARDS */
.card-row{display:grid;grid-template-columns:repeat(auto-fit,minmax(230px,1fr));gap:14px;margin-bottom:24px}
.card{background:var(--card);border:1px solid var(--border);border-radius:12px;padding:22px;position:relative;overflow:hidden;transition:border-color .25s,transform .2s}
.card:hover{border-color:var(--border2);transform:translateY(-2px)}
.card-accent{position:absolute;top:0;left:0;right:0;height:2px}
.card-accent.teal{background:linear-gradient(90deg,var(--teal),transparent)}
.card-accent.red{background:linear-gradient(90deg,var(--red),transparent)}
.card-accent.amber{background:linear-gradient(90deg,var(--amber),transparent)}
.card-accent.blue{background:linear-gradient(90deg,var(--blue),transparent)}
.card-accent.green{background:linear-gradient(90deg,var(--green),transparent)}
.card-accent.purple{background:linear-gradient(90deg,var(--purple),transparent)}
.card-icon{font-size:26px;margin-bottom:12px}
.card-label{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:2px;color:var(--txt-d);text-transform:uppercase;margin-bottom:6px}
.card-val{font-size:20px;font-weight:700;color:var(--wh);margin-bottom:8px;font-family:'DM Mono',monospace}
.card-desc{font-size:13px;color:var(--txt-d);line-height:1.6}
.card-cite{font-family:'DM Mono',monospace;font-size:10px;color:var(--teal);margin-top:8px}

/* INFO BOXES */
.info-box{border-radius:10px;padding:18px 20px;margin-bottom:16px;font-size:13.5px;line-height:1.8;border-left:3px solid}
.info-box.teal{background:var(--teal-d);border-color:var(--teal);color:var(--txt)}
.info-box.red{background:var(--red-d);border-color:var(--red);color:var(--txt)}
.info-box.amber{background:var(--amber-d);border-color:var(--amber);color:var(--txt)}
.info-box.blue{background:var(--blue-d);border-color:var(--blue);color:var(--txt)}
.info-box.green{background:var(--green-d);border-color:var(--green);color:var(--txt)}
.info-box.purple{background:var(--purple-d);border-color:var(--purple);color:var(--txt)}
.info-box strong{color:var(--wh)}
.info-box code{font-family:'DM Mono',monospace;font-size:11.5px;background:rgba(255,255,255,.07);padding:2px 6px;border-radius:3px}
sup.ref{font-family:'DM Mono',monospace;font-size:9.5px;color:var(--teal);cursor:pointer;vertical-align:super;line-height:0;transition:color .2s;padding:0 1px}
sup.ref:hover{color:var(--amber)}

/* TABLES */
.tbl-wrap{background:var(--card);border:1px solid var(--border);border-radius:12px;overflow:hidden;margin-bottom:24px}
.tbl-cap{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:1.5px;text-transform:uppercase;color:var(--txt-d);padding:12px 16px 0 16px}
.tbl-wrap table{width:100%;border-collapse:collapse}
.tbl-wrap th{background:var(--bg3);font-family:'DM Mono',monospace;font-size:10px;letter-spacing:1.5px;text-transform:uppercase;color:var(--txt-d);padding:12px 16px;text-align:left;border-bottom:1px solid var(--border)}
.tbl-wrap td{padding:13px 16px;font-size:13px;border-bottom:1px solid rgba(30,45,61,.6);vertical-align:top;line-height:1.6}
.tbl-wrap tr:last-child td{border-bottom:none}
.tbl-wrap tr:hover td{background:rgba(61,214,200,.025)}
.mono{font-family:'DM Mono',monospace;color:var(--teal);font-size:12px}
.badge{display:inline-block;padding:2px 9px;border-radius:20px;font-size:10px;font-family:'DM Mono',monospace;letter-spacing:.3px}
.badge.red{background:var(--red-d);color:var(--red);border:1px solid rgba(232,92,92,.3)}
.badge.teal{background:var(--teal-d);color:var(--teal);border:1px solid rgba(61,214,200,.3)}
.badge.amber{background:var(--amber-d);color:var(--amber);border:1px solid rgba(232,162,74,.3)}
.badge.green{background:var(--green-d);color:var(--green);border:1px solid rgba(78,203,135,.3)}
.badge.blue{background:var(--blue-d);color:var(--blue);border:1px solid rgba(90,156,245,.3)}
.badge.purple{background:var(--purple-d);color:var(--purple);border:1px solid rgba(176,126,245,.3)}

/* ACCORDION */
.accord{display:flex;flex-direction:column;gap:10px;margin-bottom:24px}
.accord-item{background:var(--card);border:1px solid var(--border);border-radius:10px;overflow:hidden}
.accord-head{display:flex;align-items:center;gap:14px;padding:16px 20px;cursor:pointer;transition:background .2s}
.accord-head:hover{background:rgba(255,255,255,.02)}
.accord-item.open .accord-head{border-bottom:1px solid var(--border)}
.accord-num{font-family:'DM Mono',monospace;font-size:11px;color:var(--teal);min-width:24px}
.accord-title{font-size:14.5px;font-weight:600;color:var(--wh);flex:1}
.accord-toggle{font-size:18px;color:var(--txt-d);transition:transform .3s}
.accord-item.open .accord-toggle{transform:rotate(45deg)}
.accord-body{font-size:13px;color:var(--txt-m);line-height:1.8;max-height:0;overflow:hidden;transition:max-height .4s ease,padding .3s;padding:0 20px}
.accord-item.open .accord-body{max-height:800px;padding:18px 20px}

/* VISUAL ELEMENTS */
.visual-box{background:var(--card);border:1px solid var(--border);border-radius:12px;padding:24px;margin-bottom:24px;overflow:hidden}
.visual-title{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:2px;text-transform:uppercase;color:var(--txt-d);margin-bottom:20px;display:flex;align-items:center;gap:8px}
.visual-title span{flex:1;height:1px;background:var(--border)}

/* Incidence Bar Chart */
.chart-bars{display:flex;align-items:flex-end;gap:12px;height:160px;margin-bottom:12px}
.bar-item{flex:1;display:flex;flex-direction:column;align-items:center;gap:6px;height:100%;justify-content:flex-end}
.bar-fill{width:100%;border-radius:4px 4px 0 0;transition:height 1.2s cubic-bezier(.4,0,.2,1);position:relative;cursor:default}
.bar-fill:hover{filter:brightness(1.2)}
.bar-val{font-family:'DM Mono',monospace;font-size:11px;font-weight:700;color:var(--wh)}
.bar-lbl{font-family:'DM Mono',monospace;font-size:9px;color:var(--txt-d);text-align:center;letter-spacing:.5px}
.chart-axis{display:flex;justify-content:space-between;margin-top:4px}
.chart-note{font-size:11px;color:var(--txt-d);font-family:'DM Mono',monospace;margin-top:8px}

/* Stage timeline */
.stage-flow{display:flex;flex-wrap:wrap;gap:0;margin-bottom:24px}
.stage-node{flex:1;min-width:160px;background:var(--card);border:1px solid var(--border);padding:18px 16px;position:relative;transition:border-color .2s}
.stage-node:hover{border-color:var(--border2)}
.stage-node:not(:last-child)::after{content:'â†’';position:absolute;right:-14px;top:50%;transform:translateY(-50%);color:var(--border2);font-size:18px;z-index:1}
.stage-node:first-child{border-radius:10px 0 0 10px}
.stage-node:last-child{border-radius:0 10px 10px 0}
.stage-num{font-family:'DM Mono',monospace;font-size:9px;color:var(--txt-d);letter-spacing:2px;text-transform:uppercase;margin-bottom:8px}
.stage-title{font-size:14px;font-weight:700;color:var(--wh);margin-bottom:6px}
.stage-detail{font-size:12px;color:var(--txt-d);line-height:1.55}
.stage-badge{display:inline-block;font-family:'DM Mono',monospace;font-size:9px;padding:2px 7px;border-radius:20px;margin-bottom:8px}

/* Algorithm flowchart */
.algo-flow{display:flex;flex-direction:column;gap:0;margin-bottom:24px}
.algo-step{display:flex;gap:16px;align-items:flex-start}
.algo-connector{display:flex;flex-direction:column;align-items:center;width:36px;flex-shrink:0}
.algo-dot{width:12px;height:12px;border-radius:50%;border:2px solid var(--teal);background:var(--bg);flex-shrink:0;margin-top:4px}
.algo-line{flex:1;width:2px;background:linear-gradient(var(--teal),rgba(61,214,200,.1));min-height:32px}
.algo-step:last-child .algo-line{display:none}
.algo-content{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:16px 18px;flex:1;margin-bottom:8px;transition:border-color .2s}
.algo-content:hover{border-color:rgba(61,214,200,.3)}
.algo-label{font-family:'DM Mono',monospace;font-size:10px;color:var(--teal);letter-spacing:1.5px;text-transform:uppercase;margin-bottom:6px}
.algo-text{font-size:13.5px;color:var(--txt);line-height:1.65}
.algo-note{font-size:12px;color:var(--txt-d);margin-top:6px}

/* Treatment regimen cards */
.rx-grid{display:grid;grid-template-columns:repeat(auto-fit,minmax(260px,1fr));gap:14px;margin-bottom:24px}
.rx-card{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:20px;position:relative;overflow:hidden}
.rx-card::before{content:'';position:absolute;top:0;left:0;right:0;height:2px}
.rx-card.primary::before{background:var(--green)}
.rx-card.secondary::before{background:var(--amber)}
.rx-card.neuro::before{background:var(--red)}
.rx-card.allergy::before{background:var(--purple)}
.rx-stage{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:1.5px;text-transform:uppercase;color:var(--txt-d);margin-bottom:8px}
.rx-drug{font-size:15px;font-weight:700;color:var(--wh);margin-bottom:4px}
.rx-dose{font-family:'DM Mono',monospace;font-size:12px;color:var(--teal);margin-bottom:8px}
.rx-detail{font-size:12px;color:var(--txt-d);line-height:1.6}

/* References */
.refs-box{background:var(--bg2);border:1px solid var(--border);border-radius:10px;padding:20px 22px;margin-top:32px}
.refs-title{font-family:'DM Mono',monospace;font-size:10px;letter-spacing:2px;text-transform:uppercase;color:var(--txt-d);margin-bottom:16px;display:flex;align-items:center;gap:10px}
.refs-title::after{content:'';flex:1;height:1px;background:var(--border)}
.ref-list{list-style:none;display:flex;flex-direction:column;gap:8px}
.ref-list li{font-size:12px;color:var(--txt-d);line-height:1.6;display:flex;gap:10px;font-family:'DM Mono',monospace}
.ref-list li .rn{color:var(--teal);min-width:22px;font-weight:700}
.ref-list li a{color:var(--blue);text-decoration:none}
.ref-list li a:hover{color:var(--teal)}

/* Section navigation button */
.sec-nav-btn{display:flex;justify-content:space-between;align-items:center;margin-top:36px;padding-top:24px;border-top:1px solid var(--border)}
.btn-prev,.btn-next-sec{display:inline-flex;align-items:center;gap:10px;padding:13px 26px;border-radius:9px;font-family:'Fraunces',serif;font-size:15px;font-weight:700;cursor:pointer;border:none;transition:all .2s;letter-spacing:.2px}
.btn-next-sec{background:linear-gradient(135deg,var(--teal),#2ab0a4);color:#071210}
.btn-next-sec:hover{transform:translateY(-2px);box-shadow:0 10px 28px rgba(61,214,200,.25)}
.btn-prev{background:none;color:var(--txt-m);border:1px solid var(--border2)}
.btn-prev:hover{border-color:var(--teal);color:var(--teal)}

/* QUIZ */
.quiz-progress{display:flex;align-items:center;justify-content:space-between;margin-bottom:20px}
.quiz-prog-label{font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d)}
.quiz-score-live{font-family:'DM Mono',monospace;font-size:12px}
.quiz-score-live .c{color:var(--green)} .quiz-score-live .w{color:var(--red)}
.quiz-card{background:var(--card);border:1px solid var(--border);border-radius:14px;padding:28px;margin-bottom:16px}
.quiz-q{font-size:17px;font-weight:600;color:var(--wh);line-height:1.45;margin-bottom:22px}
.quiz-opts{display:flex;flex-direction:column;gap:10px}
.quiz-opt{display:flex;align-items:flex-start;gap:14px;background:var(--bg3);border:1px solid var(--border);border-radius:9px;padding:14px 18px;cursor:pointer;font-size:13.5px;color:var(--txt);transition:all .2s;text-align:left}
.quiz-opt:hover:not([disabled]){border-color:rgba(61,214,200,.5);background:rgba(61,214,200,.04)}
.opt-key{font-family:'DM Mono',monospace;font-size:11px;font-weight:700;color:var(--txt-d);min-width:22px;height:22px;border:1px solid var(--border2);border-radius:4px;display:flex;align-items:center;justify-content:center;transition:all .2s;flex-shrink:0;margin-top:1px}
.quiz-opt.correct{border-color:var(--green);background:var(--green-d);color:var(--green)}
.quiz-opt.correct .opt-key{background:var(--green);color:#052;border-color:var(--green)}
.quiz-opt.wrong{border-color:var(--red);background:var(--red-d);color:var(--red)}
.quiz-opt.wrong .opt-key{background:var(--red);color:#fff;border-color:var(--red)}
.quiz-opt[disabled]{cursor:default}
.quiz-fb{border-radius:9px;padding:15px 18px;font-size:13px;line-height:1.7;display:none;margin-top:14px}
.quiz-fb.show{display:block}
.quiz-fb.ok{background:var(--green-d);border:1px solid rgba(78,203,135,.3);color:#a8ffd0}
.quiz-fb.ko{background:var(--red-d);border:1px solid rgba(232,92,92,.3);color:#ffbaba}
.quiz-actions{display:flex;justify-content:flex-end;margin-top:18px}
.btn-qnext{background:linear-gradient(135deg,var(--teal),#2ab0a4);color:#071210;border:none;border-radius:9px;padding:12px 26px;font-family:'Fraunces',serif;font-weight:700;font-size:14px;cursor:pointer;transition:transform .2s,box-shadow .2s}
.btn-qnext:hover:not([disabled]){transform:translateY(-2px);box-shadow:0 10px 24px rgba(61,214,200,.25)}
.btn-qnext[disabled]{opacity:.35;cursor:not-allowed}

/* RESULT */
.result-wrap{text-align:center;padding:48px 20px}
.result-ring-wrap{position:relative;width:168px;height:168px;margin:0 auto 28px}
.result-ring-wrap svg{transform:rotate(-90deg)}
.ring-bg{fill:none;stroke:var(--border);stroke-width:9}
.ring-fill{fill:none;stroke:var(--teal);stroke-width:9;stroke-linecap:round;stroke-dasharray:472;stroke-dashoffset:472;transition:stroke-dashoffset 1.6s cubic-bezier(.4,0,.2,1)}
.ring-text{position:absolute;inset:0;display:flex;flex-direction:column;align-items:center;justify-content:center}
.ring-pct{font-family:'DM Mono',monospace;font-size:34px;font-weight:700;color:var(--teal);line-height:1}
.ring-sub{font-size:10px;color:var(--txt-d);font-family:'DM Mono',monospace;letter-spacing:1px;margin-top:4px}
.result-title{font-size:26px;font-weight:800;color:var(--wh);margin-bottom:10px}
.result-desc{font-size:14px;color:var(--txt-d);max-width:460px;margin:0 auto 28px;line-height:1.7}
.result-stats{display:flex;gap:12px;justify-content:center;flex-wrap:wrap;margin-bottom:32px}
.stat-box{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:14px 20px;font-family:'DM Mono',monospace;text-align:center}
.stat-val{font-size:24px;font-weight:700;display:block;margin-bottom:4px}
.stat-lbl{font-size:10px;color:var(--txt-d);letter-spacing:1px}
.result-btns{display:flex;gap:12px;justify-content:center;flex-wrap:wrap}
.btn-retry{background:var(--teal-d);color:var(--teal);border:1px solid rgba(61,214,200,.3);border-radius:9px;padding:12px 26px;font-family:'Fraunces',serif;font-weight:700;font-size:14px;cursor:pointer;transition:all .2s}
.btn-retry:hover{background:rgba(61,214,200,.2)}
.btn-review-all{background:none;color:var(--txt-m);border:1px solid var(--border2);border-radius:9px;padding:12px 26px;font-family:'Fraunces',serif;font-weight:600;font-size:14px;cursor:pointer;transition:all .2s}
.btn-review-all:hover{border-color:var(--teal);color:var(--teal)}

/* HISTORY */
.hist-list{display:flex;flex-direction:column;gap:10px}
.hist-item{background:var(--card);border:1px solid var(--border);border-radius:10px;padding:16px 20px;display:flex;align-items:center;gap:16px}
.hist-rank{font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d);min-width:24px}
.hist-score{font-family:'DM Mono',monospace;font-size:20px;font-weight:700;min-width:56px}
.hist-meta{flex:1}
.hist-date{font-family:'DM Mono',monospace;font-size:11px;color:var(--txt-d)}
.hist-correct{font-size:13px;color:var(--txt-m);margin-top:2px}
.hist-medal{font-size:22px}
.empty-hist{text-align:center;padding:48px;color:var(--txt-d);font-family:'DM Mono',monospace;font-size:13px}

/* Spirochete SVG diagram */
.spiro-diagram{display:flex;justify-content:center;margin:20px 0}

@media(max-width:600px){
  .card-row{grid-template-columns:1fr}
  .rx-grid{grid-template-columns:1fr}
  .stage-flow{flex-direction:column}
  .stage-node:not(:last-child)::after{content:'â†“';right:auto;left:50%;top:auto;bottom:-20px;transform:translateX(-50%)}
  .stage-node{border-radius:0}
  .stage-node:first-child{border-radius:10px 10px 0 0}
  .stage-node:last-child{border-radius:0 0 10px 10px}
  .topbar-user{display:none}
}
</style>
</head>
<body>

<!-- LOGIN -->
<div id="loginScreen">
  <div class="login-wrap">
    <div class="login-badge">ğŸ¦  Enfeksiyon HastalÄ±klarÄ±</div>
    <h1 class="login-title"><em>Sifiliz</em><br>Klinik EÄŸitim</h1>
    <p class="login-sub">CDC 2021 Â· WHO 2024 Â· GÃ¼ncel LiteratÃ¼r</p>
    <input class="login-field" id="loginName" type="text" placeholder="AdÄ±nÄ±zÄ± girin (Ã¶rn. Dr. AyÅŸe)" maxlength="40">
    <button class="btn-login" id="loginBtn">ModÃ¼le GiriÅŸ â†’</button>
    <p class="login-note">Verileriniz yalnÄ±zca bu tarayÄ±cÄ±da saklanÄ±r.</p>
  </div>
</div>

<!-- APP -->
<div id="app">
<div class="topbar">
  <span class="topbar-brand">Sifi<span>liz</span></span>
  <div class="topbar-right">
    <span class="topbar-user" id="topbarUser"></span>
    <button class="tts-btn" id="ttsBtn">ğŸ”Š Sesli Oku</button>
    <button class="logout-btn" id="logoutBtn">Ã‡Ä±kÄ±ÅŸ</button>
  </div>
</div>
<div class="progress-track"><div class="progress-fill" id="topProgress" style="width:0%"></div></div>
<nav class="sec-nav" id="secNav">
  <button class="sec-tab active" data-sec="s1" data-prog="0">01 Â· GiriÅŸ</button>
  <button class="sec-tab" data-sec="s2" data-prog="16">02 Â· Etiyoloji</button>
  <button class="sec-tab" data-sec="s3" data-prog="32">03 Â· Epidemiyoloji</button>
  <button class="sec-tab" data-sec="s4" data-prog="48">04 Â· Klinik</button>
  <button class="sec-tab" data-sec="s5" data-prog="64">05 Â· TanÄ±</button>
  <button class="sec-tab" data-sec="s6" data-prog="80">06 Â· Tedavi</button>
  <button class="sec-tab" data-sec="sq" data-prog="100">ğŸ“ Quiz</button>
  <button class="sec-tab" data-sec="sh" data-prog="100">ğŸ† GeÃ§miÅŸ</button>
</nav>

<main class="main">

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 01 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page active" id="s1">
  <p class="page-tag">BÃ¶lÃ¼m 01 / 06</p>
  <h1 class="page-h1">Sifiliz:<br><em>BÃ¼yÃ¼k TaklitÃ§i</em></h1>
  <p class="page-intro">
    <em>Treponema pallidum</em> alt tÃ¼rÃ¼ <em>pallidum</em>'un yol aÃ§tÄ±ÄŸÄ± sifiliz; heterojen klinik tablosu, uzun inkÃ¼basyon sÃ¼resi ve pek Ã§ok hastalÄ±ÄŸÄ± taklit edebilme Ã¶zelliÄŸiyle enfeksiyon hastalÄ±klarÄ± pratiÄŸinin en Ã¶nemli konularÄ±ndan biridir.<sup class="ref">[1]</sup>
  </p>

  <div class="card-row">
    <div class="card">
      <div class="card-accent teal"></div>
      <div class="card-icon">ğŸ­</div>
      <div class="card-label">Neden "BÃ¼yÃ¼k TaklitÃ§i"?</div>
      <div class="card-desc">Primer lezyondan nÃ¶rolojik tablolara, deri dÃ¶kÃ¼ntÃ¼sÃ¼nden kardiyak bulgulara kadar Ã§ok farklÄ± klinik tablolara yol aÃ§abilir. Atipik sunumlu her hastada sifiliz ayÄ±rÄ±cÄ± tanÄ±da akÄ±lda bulunmalÄ±dÄ±r.<sup class="ref">[1,2]</sup></div>
    </div>
    <div class="card">
      <div class="card-accent amber"></div>
      <div class="card-icon">âš ï¸</div>
      <div class="card-label">GÃ¼ncel Ã–nem</div>
      <div class="card-desc">WHO'nun 2024 raporuna gÃ¶re 2022'de dÃ¼nya genelinde 8 milyon yeni eriÅŸkin sifiliz vakasÄ± ve 230.000 sifiliz iliÅŸkili Ã¶lÃ¼m bildirilmiÅŸtir.<sup class="ref">[3]</sup> Yeniden yÃ¼kselen insidans, gÃ¼nÃ¼mÃ¼zÃ¼n kritik saÄŸlÄ±k sorunlarÄ±ndan biridir.</div>
      <div class="card-cite">[3] WHO 2024</div>
    </div>
    <div class="card">
      <div class="card-accent red"></div>
      <div class="card-icon">ğŸ©º</div>
      <div class="card-label">TanÄ± OdaklÄ± YaklaÅŸÄ±m</div>
      <div class="card-desc">1943'ten bu yana penisilinine karÅŸÄ± direnÃ§ bildirilmemiÅŸtir; tedavi problemi deÄŸil, <strong>tanÄ± problemi</strong> mevcuttur.<sup class="ref">[4]</sup> Erken tanÄ± ile %100 tedavi edilebilir bir hastalÄ±ktÄ±r.</div>
    </div>
  </div>

  <div class="info-box teal">
    <strong>ğŸ’¬ William Osler (Johns Hopkins Ãœniversitesi, 1902):</strong><br>
    <em>"Sifilizi bilen biri tÄ±bbÄ± biliyordur."</em><br>
    Bu sÃ¶z gÃ¼nÃ¼mÃ¼zde de geÃ§erliliÄŸini korumakta; sifiliz geniÅŸ klinik yelpazesi nedeniyle multidisipliner bir hastalÄ±k olmaya devam etmektedir.<sup class="ref">[2]</sup>
  </div>

  <!-- Visual: Timeline -->
  <div class="section-subtitle">Tarihsel Perspektif</div>
  <div class="visual-box">
    <div class="visual-title">Sifiliz Ä°nsidansÄ±nda Kritik DÃ¶nemler <span></span></div>
    <svg viewBox="0 0 800 120" style="width:100%;height:auto">
      <defs>
        <linearGradient id="lineGrad" x1="0" y1="0" x2="1" y2="0">
          <stop offset="0%" stop-color="#e85c5c"/>
          <stop offset="40%" stop-color="#e85c5c"/>
          <stop offset="45%" stop-color="#3dd6c8"/>
          <stop offset="70%" stop-color="#3dd6c8"/>
          <stop offset="75%" stop-color="#e8a24a"/>
          <stop offset="100%" stop-color="#e85c5c"/>
        </linearGradient>
      </defs>
      <!-- baseline -->
      <line x1="40" y1="100" x2="760" y2="100" stroke="#1e2d3d" stroke-width="1"/>
      <!-- curve -->
      <path d="M40,20 C120,18 160,15 200,50 C240,80 280,90 350,88 C420,85 440,40 460,30 C480,20 500,22 540,70 C580,90 620,88 660,85 C700,82 730,60 760,45"
        fill="none" stroke="url(#lineGrad)" stroke-width="2.5" stroke-linecap="round"/>
      <!-- Milestones -->
      <circle cx="200" cy="50" r="5" fill="#3dd6c8"/>
      <text x="180" y="44" fill="#3dd6c8" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">1943</text>
      <text x="180" y="34" fill="#8aa5be" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">Penisilin</text>
      <circle cx="460" cy="30" r="5" fill="#e8a24a"/>
      <text x="460" y="24" fill="#e8a24a" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">2000'ler</text>
      <text x="460" y="14" fill="#8aa5be" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">HIV artÄ±ÅŸÄ±</text>
      <circle cx="700" cy="50" r="5" fill="#e85c5c"/>
      <text x="700" y="44" fill="#e85c5c" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">2020-24</text>
      <text x="700" y="34" fill="#8aa5be" font-size="8" font-family="DM Mono,monospace" text-anchor="middle">8M vaka/yÄ±l</text>
      <!-- Y labels -->
      <text x="28" y="24" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="end">YÃ¼ksek</text>
      <text x="28" y="95" fill="#5c7a95" font-size="8" font-family="DM Mono,monospace" text-anchor="end">DÃ¼ÅŸÃ¼k</text>
    </svg>
    <div class="chart-note">Kaynak: WHO 2024 [3], CDC 2023 [4], Peeling et al. Lancet 2023 [1]</div>
  </div>

  <div class="info-box amber">
    <strong>ğŸ“ SÄ±nav Ä°pucu:</strong> Atipik deri lezyonu, iritis/Ã¼veit, iÅŸitme kaybÄ±, nÃ¶rolojik bulgu veya kardiyak semptom gÃ¶rdÃ¼ÄŸÃ¼nÃ¼zde sifilizi <strong>mutlaka</strong> ayÄ±rÄ±cÄ± tanÄ±ya alÄ±n. HIV pozitif hastalarda sifiliz klinik tablosu atipik seyredebilir.<sup class="ref">[4]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[1]</span> Peeling RW, Mabey D, Chen XS, Garcia PJ. Syphilis. <em>Lancet</em>. 2023;402:336â€“346.</li>
      <li><span class="rn">[2]</span> Tampa M, Sarbu I, Matei C, Benea V, Georgescu SR. Brief history of syphilis. <em>J Med Life</em>. 2014;7:4â€“10.</li>
      <li><span class="rn">[3]</span> WHO. <em>Implementing the Global Health Sector Strategies on HIV, Viral Hepatitis and STIs 2022â€“2030</em>. Geneva: WHO; 2024.</li>
      <li><span class="rn">[4]</span> Workowski KA, et al. Sexually Transmitted Infections Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(No. RR-4):1â€“187.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <span></span>
    <button class="btn-next-sec" onclick="goSection('s2')">Etiyoloji & Patobiyoloji â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 02 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s2">
  <p class="page-tag">BÃ¶lÃ¼m 02 / 06</p>
  <h1 class="page-h1"><em>Etiyoloji</em> &amp;<br>Patobiyoloji</h1>
  <p class="page-intro">
    Sifilizin etkeni spiroket grubundan <em>Treponema pallidum</em> subsp. <em>pallidum</em>'dur. Mikrobiyolojik Ã¶zellikleri hem hastalÄ±ÄŸÄ±n patogenezini hem de tanÄ± algoritmalarÄ±nÄ± doÄŸrudan belirler.<sup class="ref">[5]</sup>
  </p>

  <!-- Spirochete diagram -->
  <div class="visual-box">
    <div class="visual-title">T. pallidum YapÄ±sÄ± (Åematik) <span></span></div>
    <div class="spiro-diagram">
      <svg viewBox="0 0 500 200" style="width:min(500px,100%);height:auto">
        <defs>
          <linearGradient id="sGrad" x1="0" y1="0" x2="0" y2="1">
            <stop offset="0%" stop-color="#3dd6c8" stop-opacity="0.7"/>
            <stop offset="100%" stop-color="#3dd6c8" stop-opacity="0.2"/>
          </linearGradient>
        </defs>
        <!-- Outer membrane -->
        <path d="M60,100 C80,60 120,40 160,50 C200,60 220,80 260,80 C300,80 320,60 360,50 C400,40 440,60 460,100 C440,140 400,160 360,150 C320,140 300,120 260,120 C220,120 200,140 160,150 C120,160 80,140 60,100 Z"
          fill="none" stroke="#3dd6c8" stroke-width="2" stroke-dasharray="6,3" opacity="0.6"/>
        <!-- Peptidoglycan -->
        <path d="M80,100 C100,68 135,52 170,60 C205,68 225,85 260,85 C295,85 315,68 350,60 C385,52 420,68 440,100 C420,132 385,148 350,140 C315,132 295,115 260,115 C225,115 205,132 170,140 C135,148 100,132 80,100 Z"
          fill="url(#sGrad)" stroke="#3dd6c8" stroke-width="1.5"/>
        <!-- Inner membrane -->
        <ellipse cx="260" cy="100" rx="140" ry="40" fill="#0f1520" stroke="#5a9cf5" stroke-width="1.5" opacity="0.9"/>
        <!-- Endoflagella -->
        <path d="M120,100 C150,85 190,90 230,95 C240,96 250,97 260,97" stroke="#e8a24a" stroke-width="2" fill="none" stroke-linecap="round"/>
        <path d="M400,100 C370,115 330,110 290,105 C280,104 270,103 260,103" stroke="#e8a24a" stroke-width="2" fill="none" stroke-linecap="round"/>
        <circle cx="120" cy="100" r="5" fill="#e8a24a"/>
        <circle cx="400" cy="100" r="5" fill="#e8a24a"/>
        <!-- Labels -->
        <text x="260" y="100" fill="#8aa5be" font-size="10" font-family="DM Mono,monospace" text-anchor="middle" dominant-baseline="middle">Sitoplazmik membran</text>
        <text x="260" y="72" fill="#3dd6c8" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">Peptidoglikan + DÄ±ÅŸ membran</text>
        <text x="157" y="78" fill="#e8a24a" font-size="9" font-family="DM Mono,monospace" text-anchor="end">Endoflagella</text>
        <text x="260" y="170" fill="#5c7a95" font-size="9" font-family="DM Mono,monospace" text-anchor="middle">DÄ±ÅŸ membran lipoproteinleri â†’ Antijen â†’ Serolojik tanÄ±</text>
      </svg>
    </div>
    <div class="chart-note">DÄ±ÅŸ membran lipoproteinleri hem immÃ¼n kaÃ§Ä±ÅŸa hem de serolojik testlerde kullanÄ±lan antijenlere kaynaklÄ±k eder. [5,6]</div>
  </div>

  <div class="card-row">
    <div class="card">
      <div class="card-accent teal"></div>
      <div class="card-icon">ğŸ”¬</div>
      <div class="card-label">SÄ±nÄ±flandÄ±rma</div>
      <div class="card-val">Spiroket</div>
      <div class="card-desc">Spiroket ailesi â€” <em>Treponema</em>, <em>Leptospira</em>, <em>Borrelia</em>. T. pallidum subsp. pallidum, endemik treponematoz yapan T. pallidum subsp. pertenue (frambezi) ve carateum'dan ayrÄ±lÄ±r.<sup class="ref">[5]</sup></div>
    </div>
    <div class="card">
      <div class="card-accent red"></div>
      <div class="card-icon">â±ï¸</div>
      <div class="card-label">BÃ¶lÃ¼nme HÄ±zÄ±</div>
      <div class="card-val">~30â€“33 saat</div>
      <div class="card-desc">Ã‡oÄŸu patojen bakteriye kÄ±yasla son derece yavaÅŸ bÃ¶lÃ¼nÃ¼r. Bu durum uzun inkubasyon sÃ¼resini aÃ§Ä±klar (ortalama 21 gÃ¼n, 10â€“90 gÃ¼n arasÄ±).<sup class="ref">[4]</sup></div>
    </div>
    <div class="card">
      <div class="card-accent amber"></div>
      <div class="card-icon">ğŸ§«</div>
      <div class="card-label">KÃ¼ltÃ¼r</div>
      <div class="card-val">Ãœretilemez âŒ</div>
      <div class="card-desc">T. pallidum <strong>in vitro</strong> kÃ¼ltÃ¼rde <strong>Ã¼retilemez</strong>. Bu nedenle seroloji temel tanÄ± yÃ¶ntemidir. KÃ¼ltÃ¼r kesinlikle kullanÄ±lmaz.<sup class="ref">[4,5]</sup></div>
    </div>
    <div class="card">
      <div class="card-accent blue"></div>
      <div class="card-icon">ğŸ’‰</div>
      <div class="card-label">Ä°nfektif Doz</div>
      <div class="card-val">1â€“4 bakteri</div>
      <div class="card-desc">BazÄ± kaynaklara gÃ¶re tek bir T. pallidum bile hastalÄ±k oluÅŸturmaya yetebilir. Bu olaÄŸanÃ¼stÃ¼ dÃ¼ÅŸÃ¼k infektif doz, doÄŸrudan temas sonrasÄ± hÄ±zlÄ± bulaÅŸÄ± aÃ§Ä±klar.<sup class="ref">[5]</sup></div>
    </div>
  </div>

  <div class="section-subtitle">GiriÅŸ ve Erken Patogenez</div>
  <div class="accord" id="accord-patho">
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">01</span><span class="accord-title">Mukozal geÃ§iÅŸ mekanizmasÄ±</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">T. pallidum, bÃ¼tÃ¼nlÃ¼ÄŸÃ¼ saÄŸlam mukoza yÃ¼zeylerinden mikrozal hasara ihtiyaÃ§ duymadan direkt geÃ§iÅŸ yapabilir. Deri bariyeri saÄŸlamsa geÃ§iÅŸ gerÃ§ekleÅŸmez; ancak herhangi bir epitelyal hasar varsa deri yoluyla da giriÅŸ mÃ¼mkÃ¼ndÃ¼r. OkÃ¼ler mukozaya geÃ§iÅŸ, Ã¶zellikle doÄŸum kanalÄ± temasÄ±nda ve cinsel yolla iletimde Ã¶nem taÅŸÄ±r.<sup class="ref">[4,5]</sup></div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">02</span><span class="accord-title">Fokal endarterit â€” temel patolojik lezyon</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">Sifilizin karakteristik erken patolojisi <strong>fokal obliteratif endarterit</strong>tir: tutulu damarda endotelyal proliferasyon, periadventisyal lenfoplazmasitik infiltrasyon ve damar lÃ¼meninin daralmasÄ±. Bu damarsal hasar doku iskemisine ve nekrotik Ã¼lsere yol aÃ§ar (primer ÅŸankr). AynÄ± patofizyolojik mekanizma geÃ§ dÃ¶nemde kardiyovaskÃ¼ler ve nÃ¶rolojik komplikasyonlarÄ±n da temelini oluÅŸturur.<sup class="ref">[1,5]</sup></div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">03</span><span class="accord-title">Ä°mmÃ¼n kaÃ§Ä±ÅŸ mekanizmalarÄ±</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">T. pallidum'un dÄ±ÅŸ yÃ¼zeyi lipoprotein yoÄŸunluÄŸu dÃ¼ÅŸÃ¼k olduÄŸundan immÃ¼n sistem tarafÄ±ndan geÃ§ tanÄ±nÄ±r. AyrÄ±ca konak hÃ¼creleri sararak kompleman aktivasyonundan kaÃ§abilir ve lenf nodlarÄ±na hÄ±zla yayÄ±lÄ±r. Bu Ã¶zellikler, serolojik testlerin gecikmesini ve erken dÃ¶nemde yanlÄ±ÅŸ negatif sonuÃ§larÄ± aÃ§Ä±klar.<sup class="ref">[1,5]</sup></div>
    </div>
  </div>

  <div class="info-box teal">
    <strong>ğŸ”‘ SÄ±nav NoktasÄ±:</strong> T. pallidum kÃ¼ltÃ¼rde <strong>Ã¼retilemez</strong> â†’ Seroloji temel tanÄ± yÃ¶ntemidir. KaranlÄ±k alan mikroskopisi yalnÄ±zca Ã§ok erken primer dÃ¶nemde (seroloji henÃ¼z pozitifleÅŸmemiÅŸken) kullanÄ±lÄ±r.<sup class="ref">[4]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[1]</span> Peeling RW, Mabey D, Chen XS, Garcia PJ. Syphilis. <em>Lancet</em>. 2023;402:336â€“346.</li>
      <li><span class="rn">[4]</span> Workowski KA, et al. STI Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(RR-4):1â€“187.</li>
      <li><span class="rn">[5]</span> Radolf JD, Deka RK, Anand A, et al. <em>Treponema pallidum</em>, the syphilis spirochete. <em>Nat Rev Microbiol</em>. 2016;14:744â€“759.</li>
      <li><span class="rn">[6]</span> Lafond RE, Lukehart SA. Biological basis for syphilis. <em>Clin Microbiol Rev</em>. 2006;19:29â€“49.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s1')">â† GiriÅŸ</button>
    <button class="btn-next-sec" onclick="goSection('s3')">Epidemiyoloji â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 03 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s3">
  <p class="page-tag">BÃ¶lÃ¼m 03 / 06</p>
  <h1 class="page-h1"><em>Epidemiyoloji</em><br>&amp; BulaÅŸma YollarÄ±</h1>
  <p class="page-intro">
    2022 yÄ±lÄ±nda kÃ¼resel sifiliz vakasÄ± sayÄ±sÄ± 8 milyona ulaÅŸmÄ±ÅŸ; 230.000 sifilize baÄŸlÄ± Ã¶lÃ¼m gerÃ§ekleÅŸmiÅŸtir.<sup class="ref">[3]</sup> COVID-19 pandemisi sÃ¼recinde 1,1 milyon ekstra vaka bildirilmiÅŸ olup yeniden artÄ±ÅŸ dÃ¶nemi zirvesindeyiz.<sup class="ref">[7]</sup>
  </p>

  <!-- Epidemiology Chart -->
  <div class="visual-box">
    <div class="visual-title">Global Sifiliz YÃ¼kÃ¼ â€” BÃ¶lgesel DaÄŸÄ±lÄ±m 2022 (Tahmini Yeni Vakalar) <span></span></div>
    <div class="chart-bars" id="epiChartBars">
      <div class="bar-item">
        <div class="bar-val">3.37M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#e85c5c,rgba(232,92,92,.3))" data-h="145"></div>
        <div class="bar-lbl">AMERÄ°KALAR<br>%42</div>
      </div>
      <div class="bar-item">
        <div class="bar-val">2.4M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#e8a24a,rgba(232,162,74,.3))" data-h="103"></div>
        <div class="bar-lbl">AFRÄ°KA<br>%30</div>
      </div>
      <div class="bar-item">
        <div class="bar-val">1.2M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#3dd6c8,rgba(61,214,200,.3))" data-h="52"></div>
        <div class="bar-lbl">GÃœNEY-DOÄU<br>ASYA %15</div>
      </div>
      <div class="bar-item">
        <div class="bar-val">0.72M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#5a9cf5,rgba(90,156,245,.3))" data-h="31"></div>
        <div class="bar-lbl">BATI<br>PASÄ°FÄ°K %9</div>
      </div>
      <div class="bar-item">
        <div class="bar-val">0.2M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#4ecb87,rgba(78,203,135,.3))" data-h="9"></div>
        <div class="bar-lbl">AVRUPA<br>%2.5</div>
      </div>
      <div class="bar-item">
        <div class="bar-val">0.08M</div>
        <div class="bar-fill" style="height:0;background:linear-gradient(180deg,#b07ef5,rgba(176,126,245,.3))" data-h="4"></div>
        <div class="bar-lbl">D.AKDENÄ°Z<br>%1</div>
      </div>
    </div>
    <div class="chart-note">Kaynak: PAHO/WHO 2024 [3, 7] â€” Amerika bÃ¶lgesi; 6.5/1000 kiÅŸi ile kÃ¼resel zirvede (2022).</div>
  </div>

  <div class="tbl-wrap">
    <div class="tbl-cap">Tablo 1. BulaÅŸma YollarÄ± ve Klinik Ã–nemi</div>
    <table>
      <thead><tr><th>BulaÅŸma Yolu</th><th>SÄ±klÄ±k</th><th>Klinik Not</th></tr></thead>
      <tbody>
        <tr>
          <td><strong>Cinsel temas</strong><sup class="ref">[4]</sup></td>
          <td><span class="badge red">Birincil</span></td>
          <td>Primer ve sekonder dÃ¶nemde aktif lezyonlar son derece bulaÅŸtÄ±rÄ±cÄ±dÄ±r. Oral, vajinal ve anal iliÅŸki ile bulaÅŸÄ±r. Kondom korumasÄ± %70'e kadar etki saÄŸlar.</td>
        </tr>
        <tr>
          <td><strong>Konjenital (vertikal)</strong><sup class="ref">[8]</sup></td>
          <td><span class="badge red">YÃ¼ksek</span></td>
          <td>2022'de 100.000 doÄŸumda ~57 konjenital sifiliz vakasÄ± (ABD). WHO hedefi 100.000 canlÄ± doÄŸumda â‰¤50 vakanÄ±n altÄ±na inmek. Penisilin ile Ã¶nlenebilir.</td>
        </tr>
        <tr>
          <td><strong>Kan transfÃ¼zyonu</strong><sup class="ref">[4]</sup></td>
          <td><span class="badge amber">Kontrol altÄ±nda</span></td>
          <td>Zorunlu tarama programlarÄ± baÅŸladÄ±ÄŸÄ±ndan beri klinik pratikte nadir. TÃ¼rkiye'de kan merkezlerinde sifiliz taramasÄ± zorunludur.</td>
        </tr>
        <tr>
          <td><strong>Organ nakli</strong><sup class="ref">[4]</sup></td>
          <td><span class="badge teal">Nadir</span></td>
          <td>BildirilmiÅŸ vakalar mevcut; klinik pratikte seyrek gÃ¶rÃ¼lÃ¼r. DonÃ¶r taramasÄ± ile Ã¶nlenebilir.</td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="info-box red">
    <strong>ğŸ”´ HIVâ€“Sifiliz Ko-infeksiyonu:</strong> Sifiliz tanÄ±sÄ± konan her hastada <strong>HIV araÅŸtÄ±rÄ±lmalÄ±</strong>; HIV pozitif her hastada sifiliz taranmalÄ±dÄ±r.<sup class="ref">[4]</sup> Primer/sekonder sifiliz vakalarÄ±nda HIV edinme riski 18 kat artmaktadÄ±r (1/18 kiÅŸi 1 yÄ±l iÃ§inde HIV edinir).<sup class="ref">[4]</sup> Bu <strong>eÅŸ zamanlÄ± birliktelik</strong> klinisyen iÃ§in hayati Ã¶nem taÅŸÄ±r.
  </div>

  <div class="info-box amber">
    <strong>ğŸ“Š MSM Populasyonu:</strong> CDC verileri, MSM (erkeklerle cinsel iliÅŸkiye giren erkekler) grubunda primer ve sekonder sifiliz insidansÄ±nÄ±n genel popÃ¼lasyonun Ã§ok Ã¼zerinde olduÄŸunu gÃ¶stermektedir.<sup class="ref">[4,9]</sup> Bu grup aynÄ± zamanda HIV'den en Ã§ok etkilenen popÃ¼lasyondur.
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[3]</span> WHO. <em>Global Health Sector Strategies on HIV, Viral Hepatitis and STIs 2022â€“2030</em>. 2024.</li>
      <li><span class="rn">[4]</span> Workowski KA, et al. STI Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(RR-4).</li>
      <li><span class="rn">[7]</span> PAHO/WHO. Syphilis cases increase in the Americas. News Release, May 2024.</li>
      <li><span class="rn">[8]</span> Thean L, Moore A, Nourse C. New trends in congenital syphilis. <em>Curr Opin Infect Dis</em>. 2022;35:452â€“460.</li>
      <li><span class="rn">[9]</span> Tsuboi M, Evans J, Davies EP, et al. Prevalence of syphilis among MSM: a global systematic review. <em>Lancet Glob Health</em>. 2021;9:e1110â€“e1118.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s2')">â† Etiyoloji</button>
    <button class="btn-next-sec" onclick="goSection('s4')">Klinik Evreler â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 04 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s4">
  <p class="page-tag">BÃ¶lÃ¼m 04 / 06</p>
  <h1 class="page-h1">Klinik<br><em>Evreler</em></h1>
  <p class="page-intro">
    Sifiliz dÃ¶rt ana klinik evrede deÄŸerlendirilir. Tedavi edilmezse hastalarÄ±n yaklaÅŸÄ±k %30'unda geÃ§ dÃ¶nem sifiliz geliÅŸir; geri kalanlar asemptomatik kalabilir veya hastalÄ±k latent seyreder.<sup class="ref">[4,10]</sup>
  </p>

  <!-- Stage Flow Diagram -->
  <div class="visual-box" style="padding:20px 16px">
    <div class="visual-title">Sifiliz Evreleri ve DoÄŸal Seyir <span></span></div>
    <div class="stage-flow">
      <div class="stage-node">
        <div class="stage-badge" style="background:var(--red-d);color:var(--red);border:1px solid rgba(232,92,92,.3)">1. Evre</div>
        <div class="stage-title">Primer</div>
        <div class="stage-detail">Ä°nkÃ¼basyon: 10â€“90 gÃ¼n<br>AÄŸrÄ±sÄ±z ÅŸankr + bÃ¶lgesel LAP<br>3â€“6 hafta iÃ§inde spontan iyileÅŸme</div>
      </div>
      <div class="stage-node">
        <div class="stage-badge" style="background:var(--amber-d);color:var(--amber);border:1px solid rgba(232,162,74,.3)">2. Evre</div>
        <div class="stage-title">Sekonder</div>
        <div class="stage-detail">Åankrdan 2â€“8 hafta sonra<br>Generalize dÃ¶kÃ¼ntÃ¼ (palmar/plantar)<br>Kondiloma lata, mukozal yama</div>
      </div>
      <div class="stage-node">
        <div class="stage-badge" style="background:var(--blue-d);color:var(--blue);border:1px solid rgba(90,156,245,.3)">Latent</div>
        <div class="stage-title">Latent</div>
        <div class="stage-detail">Semptom yok; seroloji (+)<br>Erken (&lt;1 yÄ±l) / GeÃ§ (&gt;1 yÄ±l)<br>Tedavi dozunu belirler</div>
      </div>
      <div class="stage-node">
        <div class="stage-badge" style="background:var(--purple-d);color:var(--purple);border:1px solid rgba(176,126,245,.3)">Tersiyer</div>
        <div class="stage-title">Tersiyer</div>
        <div class="stage-detail">NÃ¶rosifiliz (tabes, demans)<br>Kardiyak sifiliz (aortit)<br>Gomlar</div>
      </div>
    </div>
    <div class="chart-note" style="margin-top:12px">Herhangi bir evrede nÃ¶rosifiliz, okÃ¼ler sifiliz veya otosifiliz geliÅŸebilir. [4]</div>
  </div>

  <div class="section-subtitle">Evre BazlÄ± Klinik Ã–zellikler</div>
  <div class="tbl-wrap">
    <div class="tbl-cap">Tablo 2. Sifiliz Evrelerine GÃ¶re Klinik Bulgular</div>
    <table>
      <thead><tr><th>Evre</th><th>SÃ¼re / Zaman</th><th>Karakteristik Bulgular</th><th>Ã–nemli Notlar</th></tr></thead>
      <tbody>
        <tr>
          <td><span class="badge red">Primer</span></td>
          <td class="mono">10â€“90 gÃ¼n</td>
          <td>Tek aÄŸrÄ±sÄ±z, sert kenarlÄ± Ã¼lser (ÅŸankr); bÃ¶lgesel aÄŸrÄ±sÄ±z lenfadenopati</td>
          <td>Atipik: Ã§oklu, aÄŸrÄ±lÄ± veya ekstragenityal lezyonlar olabilir<sup class="ref">[4]</sup></td>
        </tr>
        <tr>
          <td><span class="badge amber">Sekonder</span></td>
          <td class="mono">Åankrdan 2â€“8 hafta sonra</td>
          <td>MakÃ¼lopapÃ¼ler dÃ¶kÃ¼ntÃ¼ (<strong>avuÃ§ iÃ§i + ayak tabanÄ±</strong>), kondiloma lata, mukozal yamalar, lenfadenopati</td>
          <td>Sistemik: ateÅŸ, hepatit, Ã¼veit/iritis, kranyal sinir felci olabilir<sup class="ref">[4,10]</sup></td>
        </tr>
        <tr>
          <td><span class="badge blue">Erken Latent</span></td>
          <td class="mono">Ä°lk 1 yÄ±l</td>
          <td>Semptom yok; seroloji reaktif</td>
          <td>BulaÅŸtÄ±rÄ±cÄ±lÄ±k devam edebilir; vertikal geÃ§iÅŸ riski mevcut<sup class="ref">[4]</sup></td>
        </tr>
        <tr>
          <td><span class="badge blue">GeÃ§ Latent</span></td>
          <td class="mono">&gt;1 yÄ±l</td>
          <td>Semptom yok; seroloji reaktif</td>
          <td>Tedavi sÃ¼resi daha uzun (3 haftalÄ±k rejim); bulaÅŸtÄ±rÄ±cÄ±lÄ±k dÃ¼ÅŸÃ¼k<sup class="ref">[4]</sup></td>
        </tr>
        <tr>
          <td><span class="badge purple">Tersiyer</span></td>
          <td class="mono">YÄ±llarca sonra (%30)</td>
          <td>NÃ¶rosifiliz, kardiyovaskÃ¼ler sifiliz (aortit, aort yetmezliÄŸi), gomlar</td>
          <td>Penisilin Ã¶ncesi dÃ¶nemin major komplikasyonlarÄ±; gÃ¼nÃ¼mÃ¼zde seyrek<sup class="ref">[4,10]</sup></td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="info-box teal">
    <strong>ğŸ“Œ Patognomonik Bulgu â€” SÄ±nav Favorisi!</strong> Sekonder sifilizde <strong>avuÃ§ iÃ§i (palmar) ve ayak tabanÄ± (plantar) dÃ¶kÃ¼ntÃ¼sÃ¼</strong> son derece karakteristiktir. Bu bulgu + aÄŸrÄ±sÄ±z ÅŸankr Ã¶ykÃ¼sÃ¼ = sifiliz tanÄ±sÄ± neredeyse kesindir.<sup class="ref">[4,10]</sup>
  </div>

  <div class="info-box red">
    <strong>âš¡ GÃ¼ncel UyarÄ± â€” OkÃ¼ler ve Otosifiliz:</strong> CDC 2021 kÄ±lavuzuna gÃ¶re okÃ¼ler (Ã¼veit, iritis, optik nÃ¶rit) ve otosifiliz (ani iÅŸitme kaybÄ±, tinnitus) <strong>herhangi bir evrede</strong> geliÅŸebilir ve nÃ¶rosifiliz ile aynÄ± protokolde tedavi edilmelidir.<sup class="ref">[4]</sup> NÃ¶rosifiliz semptomlarÄ± olan her hastaya BOS analizi Ã¶nerilir.
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[4]</span> Workowski KA, et al. STI Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(RR-4):1â€“187.</li>
      <li><span class="rn">[10]</span> Tuddenham S, et al. Syphilis. <em>N Engl J Med</em>. 2022;387:1906â€“1918.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s3')">â† Epidemiyoloji</button>
    <button class="btn-next-sec" onclick="goSection('s5')">TanÄ± AlgoritmasÄ± â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 05 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s5">
  <p class="page-tag">BÃ¶lÃ¼m 05 / 06</p>
  <h1 class="page-h1">TanÄ±<br><em>AlgoritmasÄ±</em></h1>
  <p class="page-intro">
    Sifiliz tanÄ±sÄ± hem klinik bulgulara hem de serolojiye dayanÄ±r. Hangi testin ne zaman, hangi biyolojik Ã¶rnekte kullanÄ±lacaÄŸÄ±nÄ± bilmek kritik Ã¶neme sahiptir.<sup class="ref">[4,11]</sup>
  </p>

  <!-- Decision Algorithm -->
  <div class="visual-box">
    <div class="visual-title">CDC 2021 TanÄ± AkÄ±ÅŸ ÅemasÄ±<sup class="ref">[4]</sup> <span></span></div>
    <div class="algo-flow">
      <div class="algo-step">
        <div class="algo-connector"><div class="algo-dot"></div><div class="algo-line"></div></div>
        <div class="algo-content">
          <div class="algo-label">Klinik DeÄŸerlendirme</div>
          <div class="algo-text">ÅÃ¼pheli lezyon veya risk faktÃ¶rÃ¼ mevcut mu?</div>
          <div class="algo-note">Atipik sunumda sifilizi her zaman ayÄ±rÄ±cÄ± tanÄ±da dÃ¼ÅŸÃ¼n</div>
        </div>
      </div>
      <div class="algo-step">
        <div class="algo-connector"><div class="algo-dot"></div><div class="algo-line"></div></div>
        <div class="algo-content">
          <div class="algo-label">âš¡ Ã‡ok Erken DÃ¶nem (Seroloji HenÃ¼z Negatif)</div>
          <div class="algo-text"><code>KaranlÄ±k alan mikroskopisi</code> veya <code>Direkt floresan antikor boyama</code> â†’ Aktif lezyondan spiroketi gÃ¶ster</div>
          <div class="algo-note">YalnÄ±zca bu dÃ¶nemde endikedir; rutin pratikte kullanÄ±mÄ± kÄ±sÄ±tlÄ±dÄ±r</div>
        </div>
      </div>
      <div class="algo-step">
        <div class="algo-connector"><div class="algo-dot"></div><div class="algo-line"></div></div>
        <div class="algo-content">
          <div class="algo-label">Tarama â€” Non-treponemal Test</div>
          <div class="algo-text"><code>RPR</code> (Rapid Plasma Reagin) veya <code>VDRL</code> (Venereal Disease Research Lab)</div>
          <div class="algo-note"><strong>Kantitatif Ã¶lÃ§Ã¼lÃ¼r â†’ HastalÄ±k aktivitesini ve tedavi yanÄ±tÄ±nÄ± izlemede kullanÄ±lÄ±r</strong><sup class="ref">[4]</sup></div>
        </div>
      </div>
      <div class="algo-step">
        <div class="algo-connector"><div class="algo-dot"></div><div class="algo-line"></div></div>
        <div class="algo-content">
          <div class="algo-label">DoÄŸrulama â€” Treponemal Test</div>
          <div class="algo-text"><code>FTA-ABS</code> (floresan antikor boyama) veya <code>TP-PA</code> / <code>TPHA</code> (partikÃ¼l aglÃ¼tinasyon)</div>
          <div class="algo-note">Tedaviden baÄŸÄ±msÄ±z, Ã¶mÃ¼r boyu pozitif kalabilir â†’ aktivite takibinde kullanÄ±lmaz<sup class="ref">[4]</sup></div>
        </div>
      </div>
      <div class="algo-step">
        <div class="algo-connector"><div class="algo-dot" style="border-color:var(--red)"></div><div class="algo-line" style="background:linear-gradient(var(--red),rgba(232,92,92,.1))"></div></div>
        <div class="algo-content" style="border-color:rgba(232,92,92,.3)">
          <div class="algo-label" style="color:var(--red)">NÃ¶rosifiliz ÅÃ¼phesi â€” BOS Analizi</div>
          <div class="algo-text"><code>BOS-VDRL</code> (yÃ¼ksek Ã¶zgÃ¼llÃ¼k, dÃ¼ÅŸÃ¼k duyarlÄ±lÄ±k) veya <code>BOS-PCR</code> (tercih edilen, ancak eriÅŸimi kÄ±sÄ±tlÄ±)</div>
          <div class="algo-note"><strong>BOS'ta RPR, FTA-ABS veya TPHA kullanÄ±lmaz</strong><sup class="ref">[4]</sup> â€” sÄ±nav sorusu!</div>
        </div>
      </div>
    </div>
  </div>

  <div class="section-subtitle">Serolojik Test Ã–zeti</div>
  <div class="tbl-wrap">
    <div class="tbl-cap">Tablo 3. Sifiliz Serolojik Testlerinin KarÅŸÄ±laÅŸtÄ±rmasÄ±</div>
    <table>
      <thead><tr><th>Test Grubu</th><th>Testler</th><th>Mekanizma</th><th>Ã–zellik</th><th>KullanÄ±m</th></tr></thead>
      <tbody>
        <tr>
          <td><span class="badge amber">Non-treponemal</span></td>
          <td class="mono">RPR, VDRL</td>
          <td>Kardiyolipin + lesitin antikorlarÄ± (sifilize Ã¶zgÃ¼ deÄŸil)</td>
          <td>Kantitatif Ã¶lÃ§Ã¼lÃ¼r; hastalÄ±k aktivitesi ile korelasyon<sup class="ref">[4]</sup></td>
          <td>Tarama, tedavi takibi</td>
        </tr>
        <tr>
          <td><span class="badge teal">Treponemal</span></td>
          <td class="mono">FTA-ABS, TP-PA/TPHA, EIA/CIA</td>
          <td>T. pallidum'a Ã¶zgÃ¼ antijenler</td>
          <td>Daha Ã¶zgÃ¼l; tedaviden baÄŸÄ±msÄ±z pozitif kalÄ±r<sup class="ref">[4]</sup></td>
          <td>DoÄŸrulama testi</td>
        </tr>
        <tr>
          <td><span class="badge red">BOS (NÃ¶rosifiliz)</span></td>
          <td class="mono">BOS-VDRL veya BOS-PCR</td>
          <td>BOS'ta sifilize ait antikor/DNA</td>
          <td>BOS-VDRL: yÃ¼ksek Ã¶zgÃ¼llÃ¼k, dÃ¼ÅŸÃ¼k duyarlÄ±lÄ±k<sup class="ref">[4,12]</sup></td>
          <td>NÃ¶rosifiliz tanÄ±sÄ±</td>
        </tr>
      </tbody>
    </table>
  </div>

  <div class="accord" id="accord-tani">
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ’¡</span><span class="accord-title">Non-treponemal titre ve tedavi takibi â€” kritik bilgi</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        CDC 2021 kÄ±lavuzuna gÃ¶re: Primer/sekonder sifiliz tedavisinden 12 ay iÃ§inde titre 4 kat azalmalÄ±dÄ±r. GeÃ§ latent/tersiyer sifilizde 24 aylÄ±k sÃ¼re beklenir. Titre 4 kat artarsa veya dÃ¼ÅŸmezse â†’ tedavi baÅŸarÄ±sÄ±zlÄ±ÄŸÄ± veya yeniden enfeksiyon; BOS analizi ve HIV tetkiki Ã¶nerilir.<sup class="ref">[4]</sup> Treponemal testler bu amaÃ§la kullanÄ±lmaz; tedavi sonrasÄ± da pozitif kalmaya devam ederler.<sup class="ref">[4]</sup>
      </div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ’¡</span><span class="accord-title">YanlÄ±ÅŸ pozitif non-treponemal test durumlarÄ±</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        Biyolojik yanlÄ±ÅŸ pozitiflik: SLE, hamilelik, IV ilaÃ§ kullanÄ±mÄ±, yaÅŸlÄ±lÄ±k, Lyme hastalÄ±ÄŸÄ±, viral enfeksiyonlar (EBV, HIV). Bu durumlarda RPR/VDRL reaktif Ã§Ä±kabilir ancak FTA-ABS/TP-PA negatif olur. TanÄ± iÃ§in her iki test grubu da birlikte deÄŸerlendirilmelidir.<sup class="ref">[4,11]</sup>
      </div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ’¡</span><span class="accord-title">NÃ¶rosifiliz tanÄ± kriterleri</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        Tek bir test tÃ¼m olgularda tanÄ± koyduramamaktadÄ±r. TanÄ±; BOS hÃ¼cre sayÄ±sÄ± (>10 BK/mmÂ³), BOS protein (>50 mg/dL), reaktif BOS-VDRL ve klinik bulgular kombinasyonuna dayanÄ±r. BOS-VDRL yÃ¼ksek Ã¶zgÃ¼llÃ¼klÃ¼ (reaktifse tanÄ± konur) ancak dÃ¼ÅŸÃ¼k duyarlÄ±lÄ±klÄ±dÄ±r. HIV pozitif hastalarda BOS'ta patolojik lÃ¶kosit sÄ±nÄ±rÄ± >20 BK/mmÂ³ olarak kabul edilmektedir.<sup class="ref">[4,12]</sup>
      </div>
    </div>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[4]</span> Workowski KA, et al. STI Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(RR-4):1â€“187.</li>
      <li><span class="rn">[11]</span> Peeling RW, Mabey D, Herring AJ, Holmes KK. Rapid tests for sexually transmitted infections. <em>Nat Rev Microbiol</em>. 2006;4(12 Suppl):S6â€“13.</li>
      <li><span class="rn">[12]</span> Marra CM, et al. Normalization of serum RPR titer predicts normalization of CSF-VDRL titer following neurosyphilis treatment. <em>Sex Transm Infect</em>. 2012;88:597â€“602.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s4')">â† Klinik Evreler</button>
    <button class="btn-next-sec" onclick="goSection('s6')">Tedavi â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• BÃ–LÃœM 06 â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="s6">
  <p class="page-tag">BÃ¶lÃ¼m 06 / 06</p>
  <h1 class="page-h1">Tedavi &amp;<br><em>Ã–zel Durumlar</em></h1>
  <p class="page-intro">
    Sifiliz tedavisinde <strong>penisilin G</strong> altÄ±n standarttÄ±r. 1943'ten bu yana T. pallidum'da penisilinine karÅŸÄ± direnÃ§ bildirilmemiÅŸtir.<sup class="ref">[4]</sup> Penisilin preparatÄ±, dozu ve sÃ¼resi evreye ve klinik tabloya gÃ¶re belirlenir.
  </p>

  <div class="info-box red">
    <strong>âš ï¸ CDC 2021 UyarÄ±sÄ±:</strong> Benzatin penisilin G (Bicillin L-A) ile kombinasyon preparat Bicillin C-R <strong>birbirinin yerine kullanÄ±lamaz</strong>. Ã–zellikle eczane ve satÄ±n alma sÃ¼reÃ§lerinde bu iki Ã¼rÃ¼nÃ¼n karÄ±ÅŸtÄ±rÄ±lmamasÄ± kritik Ã¶neme sahiptir.<sup class="ref">[4]</sup>
  </div>

  <div class="section-subtitle">CDC 2021 Tedavi Rejimleri</div>
  <div class="rx-grid">
    <div class="rx-card primary">
      <div class="rx-stage">Primer / Sekonder / Erken Latent (â‰¤1 yÄ±l)</div>
      <div class="rx-drug">Benzatin Penisilin G</div>
      <div class="rx-dose">2,4 milyon IU IM â€” Tek Doz</div>
      <div class="rx-detail">Her Ã¼Ã§ evre iÃ§in tek enjeksiyon yeterlidir. Ek doz vermenin etkinliÄŸi artÄ±rmadÄ±ÄŸÄ± kanÄ±tlanmÄ±ÅŸtÄ±r.<sup class="ref">[4]</sup></div>
    </div>
    <div class="rx-card secondary">
      <div class="rx-stage">GeÃ§ Latent / Bilinmeyen SÃ¼re / GommatÃ¶z</div>
      <div class="rx-drug">Benzatin Penisilin G</div>
      <div class="rx-dose">2,4 milyon IU IM â€” Haftada 1 Ã— 3 Doz</div>
      <div class="rx-detail">Toplam 7,2 milyon IU. Dozlar arasÄ± sÃ¼re 10â€“14 gÃ¼nÃ¼ geÃ§memelidir. Gecikme varsa baÅŸa dÃ¶nÃ¼lÃ¼r.<sup class="ref">[4]</sup></div>
    </div>
    <div class="rx-card neuro">
      <div class="rx-stage">NÃ¶rosifiliz / OkÃ¼ler Sifiliz / Otosifiliz</div>
      <div class="rx-drug">Kristalize Penisilin G IV</div>
      <div class="rx-dose">18â€“24 milyon IU/gÃ¼n (3â€“4 mIU q4s) Ã— 10â€“14 gÃ¼n</div>
      <div class="rx-detail">Alternatif: Prokain Penisilin G 2,4 mIU/gÃ¼n IM + Probenesit 500 mg 4Ã—1 oral Ã— 10â€“14 gÃ¼n (uyum saÄŸlanabilirse). SonrasÄ±nda Benz-PenG 2,4 mIU/hafta Ã— 3 doz eklenebilir.<sup class="ref">[4,13]</sup></div>
    </div>
    <div class="rx-card allergy">
      <div class="rx-stage">Penisilin Alerjisi (Ciddi) â€” Non-hamile, Non-nÃ¶ro</div>
      <div class="rx-drug">Doksisiklin</div>
      <div class="rx-dose">100 mg 2Ã—1 po â€” 14 gÃ¼n (erken) / 28 gÃ¼n (geÃ§ latent)</div>
      <div class="rx-detail">Temas sonrasÄ± profilakside de kullanÄ±lÄ±r (Doxy-PEP). NÃ¶rosifilizde penisilin alerjisine raÄŸmen desensitizasyon Ã¶nerilir. Gebelikte kontrendike.<sup class="ref">[4]</sup></div>
    </div>
  </div>

  <!-- Probenesid mechanism visual -->
  <div class="visual-box">
    <div class="visual-title">Probenesit MekanizmasÄ± â€” Neden Eklenir? <span></span></div>
    <svg viewBox="0 0 600 130" style="width:100%;height:auto">
      <!-- Kidney -->
      <ellipse cx="100" cy="65" rx="55" ry="45" fill="#131b25" stroke="#1e2d3d" stroke-width="1.5"/>
      <text x="100" y="62" fill="#8aa5be" font-size="11" text-anchor="middle" font-family="DM Mono,monospace">BÃ¶brek</text>
      <text x="100" y="76" fill="#5c7a95" font-size="9" text-anchor="middle" font-family="DM Mono,monospace">TÃ¼bÃ¼ler sekresyon</text>
      <!-- Arrow normal (X) -->
      <path d="M160,65 L240,65" stroke="#e85c5c" stroke-width="2" marker-end="url(#arrowRed)"/>
      <text x="200" y="58" fill="#e85c5c" font-size="9" text-anchor="middle" font-family="DM Mono,monospace">HÄ±zlÄ± atÄ±lÄ±m</text>
      <!-- Blood stream -->
      <rect x="260" y="40" width="90" height="50" rx="8" fill="#131b25" stroke="#3dd6c8" stroke-width="1.5"/>
      <text x="305" y="62" fill="#3dd6c8" font-size="10" text-anchor="middle" font-family="DM Mono,monospace">PenisilinG</text>
      <text x="305" y="76" fill="#5c7a95" font-size="9" text-anchor="middle" font-family="DM Mono,monospace">Kanda uzun</text>
      <!-- Probenecid block -->
      <rect x="168" y="78" width="68" height="20" rx="4" fill="#b07ef5" opacity="0.2"/>
      <text x="202" y="92" fill="#b07ef5" font-size="8.5" text-anchor="middle" font-family="DM Mono,monospace">Probenesit âŒ</text>
      <!-- Arrow to CNS -->
      <path d="M355,65 L440,65" stroke="#3dd6c8" stroke-width="2"/>
      <text x="397" y="58" fill="#3dd6c8" font-size="9" text-anchor="middle" font-family="DM Mono,monospace">YÃ¼ksek konstr</text>
      <!-- CNS -->
      <ellipse cx="500" cy="65" rx="60" ry="40" fill="#131b25" stroke="#5a9cf5" stroke-width="1.5"/>
      <text x="500" y="62" fill="#5a9cf5" font-size="11" text-anchor="middle" font-family="DM Mono,monospace">BOS / SSS</text>
      <text x="500" y="76" fill="#5c7a95" font-size="9" text-anchor="middle" font-family="DM Mono,monospace">TerapÃ¶tik dÃ¼zey</text>
      <defs>
        <marker id="arrowRed" markerWidth="6" markerHeight="6" refX="3" refY="3" orient="auto">
          <path d="M0,0 L6,3 L0,6 Z" fill="#e85c5c"/>
        </marker>
      </defs>
    </svg>
    <div class="chart-note">Probenesit, renal tÃ¼bÃ¼ler sekresyonu inhibe ederek penisilinin plazma konsantrasyonunu ve BOS dÃ¼zeyini uzun sÃ¼re terapÃ¶tik seviyede tutar. [4,13]</div>
  </div>

  <div class="section-subtitle">Ã–zel Klinik Durumlar</div>
  <div class="accord" id="accord-special">
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ”¥</span><span class="accord-title">Jarisch-Herxheimer Reaksiyonu</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        Ä°lk tedavi dozundan sonraki <strong>2â€“8 saat iÃ§inde</strong> gÃ¶rÃ¼lÃ¼r; Ã¶len spiroketten aÃ§Ä±ÄŸa Ã§Ä±kan lipoproteinlerin TLR2 aracÄ±lÄ± inflamatuar kaskad oluÅŸturmasÄ± sonucu geliÅŸir. Klinik: ateÅŸ, titreme, miyalji, baÅŸaÄŸrÄ±sÄ±, taÅŸikardi, hipotansiyon. Genellikle 24 saatte geÃ§er. TÃ¼m spiroket infeksiyonlarÄ±nda gÃ¶rÃ¼lebilir; penisilin alerjisi ile karÄ±ÅŸtÄ±rÄ±lmamalÄ±dÄ±r. Semptomatik tedavi (antipiretik, hidrasyon) yeterlidir.<sup class="ref">[4,14]</sup>
      </div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ¤°</span><span class="accord-title">Gebelikte Sifiliz</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        <strong>Penisilin zorunludur</strong>; doksisiklin gebelikte kontrendikedir. Penisilin alerjisi varsa desensitizasyon protokolÃ¼ uygulanmalÄ±dÄ±r. Konjenital sifilizi Ã¶nlemede benzatin PenG 2,4 mIU dozu; klinik sifilizi %97, Ã¶lÃ¼ doÄŸumu %82, preterm doÄŸumu %64 azaltÄ±r.<sup class="ref">[8,4]</sup> Geciken doz (&gt;9 gÃ¼n aralÄ±k) durumunda tÃ¼m kÃ¼r yeniden baÅŸlanÄ±r.
      </div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ¦ </span><span class="accord-title">HIV-Sifiliz Ko-infeksiyonu</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        HIV pozitif hastalarda sifiliz klinik tablosu atipik seyredebilir; serolojik yanÄ±t gecikebilir veya yanlÄ±ÅŸ negatif/pozitif sonuÃ§lar gÃ¶zlenebilir. Tedavi rejimleri HIV negatif hastalarla aynÄ±dÄ±r; ancak ek benzatin PenG dozlarÄ± etkinliÄŸi artÄ±rmaz. 6 ve 12. aylarda serolojik takip Ã¶nerilir. NÃ¶rosifiliz riski HIV pozitif hastalarda daha yÃ¼ksektir.<sup class="ref">[4,13]</sup>
      </div>
    </div>
    <div class="accord-item">
      <div class="accord-head"><span class="accord-num">ğŸ¯</span><span class="accord-title">Temas SonrasÄ± Profilaksi (Doxy-PEP)</span><span class="accord-toggle">+</span></div>
      <div class="accord-body">
        CDC 2021 kÄ±lavuzu doksisiklin post-exposure profilaksisini (Doxy-PEP) sifiliz ve klamidya iÃ§in etkin bir strateji olarak deÄŸerlendirmiÅŸtir. YÃ¼ksek riskli MSM popÃ¼lasyonunda cinsel temastan sonraki 72 saat iÃ§inde doksisiklin 200 mg tek doz uygulamasÄ± bakteriyel STI riskini Ã¶nemli Ã¶lÃ§Ã¼de azaltmaktadÄ±r.<sup class="ref">[4]</sup>
      </div>
    </div>
  </div>

  <div class="info-box green">
    <strong>âœ… Serologic Follow-Up Ã–zeti (CDC 2021):</strong> Primer/sekonder sifiliz sonrasÄ± <strong>6. ve 12. aylarda</strong> RPR/VDRL takibi Ã¶nerilir. GeÃ§ latent sonrasÄ± <strong>6., 12. ve 24. aylarda</strong> kontrol yapÄ±lÄ±r. HIV pozitif hastalarda <strong>3., 6., 9., 12. ve 24. aylarda</strong> takip planlanÄ±r.<sup class="ref">[4]</sup>
  </div>

  <div class="refs-box">
    <div class="refs-title">BÃ¶lÃ¼m KaynaklarÄ± <span></span></div>
    <ol class="ref-list">
      <li><span class="rn">[4]</span> Workowski KA, et al. STI Treatment Guidelines, 2021. <em>MMWR Recomm Rep</em>. 2021;70(RR-4):1â€“187.</li>
      <li><span class="rn">[8]</span> Thean L, Moore A, Nourse C. New trends in congenital syphilis. <em>Curr Opin Infect Dis</em>. 2022;35:452â€“460.</li>
      <li><span class="rn">[13]</span> Marra CM, Maxwell CL, Tantalo LC, et al. Normalization of serum RPR titer after neurosyphilis treatment: comparison of IV vs IM procaine penicillin + probenecid. <em>Clin Infect Dis</em>. 2021;72:1411â€“1417.</li>
      <li><span class="rn">[14]</span> Butler T. The Jarisch-Herxheimer reaction after antibiotic treatment of spirochetal infections. <em>J Infect</em>. 2017;74:207â€“212.</li>
    </ol>
  </div>
  <div class="sec-nav-btn">
    <button class="btn-prev" onclick="goSection('s5')">â† TanÄ±</button>
    <button class="btn-next-sec" onclick="goSection('sq')">ğŸ“ Quiz'e BaÅŸla â†’</button>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• QUIZ â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="sq">
  <p class="page-tag">Bilgi Testi</p>
  <h1 class="page-h1">Sifiliz<br><em>Quiz</em></h1>
  <div id="quizMain">
    <div class="quiz-progress">
      <span class="quiz-prog-label" id="qProgLabel">Soru 1 / 10</span>
      <span class="quiz-score-live">DoÄŸru: <span class="c" id="qCorrect">0</span> &nbsp;|&nbsp; YanlÄ±ÅŸ: <span class="w" id="qWrong">0</span></span>
    </div>
    <div class="quiz-card">
      <div class="quiz-q" id="qText"></div>
      <div class="quiz-opts" id="qOpts"></div>
      <div class="quiz-fb" id="qFb"></div>
    </div>
    <div class="quiz-actions">
      <button class="btn-qnext" id="btnNext" disabled>Sonraki â†’</button>
    </div>
  </div>
  <div id="quizResult" style="display:none">
    <div class="result-wrap">
      <div class="result-ring-wrap">
        <svg width="168" height="168" viewBox="0 0 168 168"><circle class="ring-bg" cx="84" cy="84" r="75"/><circle class="ring-fill" id="ringFill" cx="84" cy="84" r="75"/></svg>
        <div class="ring-text"><span class="ring-pct" id="rPct">0%</span><span class="ring-sub">BAÅARI</span></div>
      </div>
      <div class="result-title" id="rTitle">â€”</div>
      <div class="result-desc" id="rDesc">â€”</div>
      <div class="result-stats">
        <div class="stat-box"><span class="stat-val" id="rCorrect" style="color:var(--green)">0</span><span class="stat-lbl">DOÄRU</span></div>
        <div class="stat-box"><span class="stat-val" id="rWrong" style="color:var(--red)">0</span><span class="stat-lbl">YANLIÅ</span></div>
        <div class="stat-box"><span class="stat-val" style="color:var(--amber)">10</span><span class="stat-lbl">TOPLAM</span></div>
      </div>
      <div class="result-btns">
        <button class="btn-retry" id="btnRetry">ğŸ”„ Tekrar Et</button>
        <button class="btn-review-all" id="btnReview">ğŸ“š ModÃ¼lÃ¼ Ä°ncele</button>
      </div>
    </div>
  </div>
</div>

<!-- â•â•â•â•â•â•â•â•â•â•â•â•â•â• GEÃ‡MÄ°Å â•â•â•â•â•â•â•â•â•â•â•â•â•â• -->
<div class="sec-page" id="sh">
  <p class="page-tag">Puan GeÃ§miÅŸi</p>
  <h1 class="page-h1"><em>Quiz</em> GeÃ§miÅŸi</h1>
  <p class="page-intro">TÃ¼m quiz denemelerinizin kayÄ±tlarÄ± burada listelenmektedir.</p>
  <div id="histList"></div>
</div>

</main>
</div><!-- /app -->

<script>
// â•â•â•â• QUESTIONS â•â•â•â•
const QUESTIONS=[
  {q:"WHO 2024 verilerine gÃ¶re 2022 yÄ±lÄ±nda kÃ¼resel sifiliz vaka sayÄ±sÄ± ve Ã¶lÃ¼m oranÄ± nedir?",opts:["4 milyon vaka / 100.000 Ã¶lÃ¼m","8 milyon yeni vaka / 230.000 Ã¶lÃ¼m","12 milyon vaka / 500.000 Ã¶lÃ¼m","2 milyon vaka / 50.000 Ã¶lÃ¼m"],ans:1,fb:"WHO 2024 raporuna gÃ¶re 2022'de dÃ¼nya genelinde 8 milyon yeni eriÅŸkin sifiliz vakasÄ± ve 230.000 sifiliz iliÅŸkili Ã¶lÃ¼m bildirilmiÅŸtir. Yeniden yÃ¼kselen insidans CDC'nin 2000'li yÄ±llardan bu yana gÃ¶zlemlediÄŸi trendin devamÄ±dÄ±r. [WHO 2024]"},
  {q:"T. pallidum ile ilgili hangisi kesinlikle doÄŸrudur?",opts:["KÃ¼ltÃ¼rde kolayca Ã¼retilir","BÃ¶lÃ¼nme sÃ¼resi ~4 saattir","KÃ¼ltÃ¼rde Ã¼retilemez; bu tanÄ±da serolojiye baÅŸvurulmasÄ±nÄ± zorunlu kÄ±lar","Penisiline karÅŸÄ± son yÄ±llarda direnÃ§ geliÅŸmiÅŸtir"],ans:2,fb:"T. pallidum in vitro kÃ¼ltÃ¼rde Ã¼retilemez â€” bu sifiliz biyolojisinin temel Ã¶zelliÄŸidir. BÃ¶lÃ¼nme sÃ¼resi ~30-33 saattir. Penisiline karÅŸÄ± 1943'ten bu yana herhangi bir direnÃ§ bildirilmemiÅŸtir. [CDC 2021]"},
  {q:"CDC 2021 kÄ±lavuzuna gÃ¶re primer sifiliz tedavisi nedir?",opts:["Benzatin penisilin G 2,4 mIU IM tek doz","Benzatin penisilin G 2,4 mIU IM Ã— 3 hafta","Kristalize penisilin G 18â€“24 mIU/gÃ¼n IV Ã— 14 gÃ¼n","Doksisiklin 100 mg 2Ã—1 Ã— 28 gÃ¼n"],ans:0,fb:"Primer, sekonder ve erken latent sifiliz (<1 yÄ±l) iÃ§in benzatin penisilin G 2,4 milyon IU IM tek doz Ã¶nerilir. Ek doz verilmesinin etkinliÄŸi artÄ±rmadÄ±ÄŸÄ± kanÄ±tlanmÄ±ÅŸtÄ±r. [CDC 2021]"},
  {q:"NÃ¶rosifiliz tedavisinde BOS'ta hangi test tercih edilir?",opts:["RPR","FTA-ABS","TPHA","BOS-VDRL veya BOS-PCR"],ans:3,fb:"BOS'ta VDRL veya PCR kullanÄ±lÄ±r. RPR, FTA-ABS ve TPHA BOS tanÄ±sÄ± iÃ§in Ã¶nerilmez. BOS-VDRL yÃ¼ksek Ã¶zgÃ¼llÃ¼klÃ¼dÃ¼r; reaktifse tanÄ± neredeyse kesindir. Ancak duyarlÄ±lÄ±ÄŸÄ± dÃ¼ÅŸÃ¼ktÃ¼r. [CDC 2021]"},
  {q:"CDC 2021'e gÃ¶re nÃ¶rosifiliz iÃ§in birincil tedavi rejimi nedir?",opts:["Benzatin penisilin G 2,4 mIU/hafta Ã— 3 doz","Kristalize penisilin G 18â€“24 mIU/gÃ¼n IV (3â€“4 mIU q4s) Ã— 10â€“14 gÃ¼n","Doksisiklin 100 mg 2Ã—1 Ã— 28 gÃ¼n","Prokain penisilin G IM Ã— 21 gÃ¼n"],ans:1,fb:"NÃ¶rosifiliz (ayrÄ±ca okÃ¼ler ve otosifiliz) iÃ§in: Kristalize penisilin G 18-24 milyon IU/gÃ¼n IV, 3-4 milyon IU q4s veya sÃ¼rekli infÃ¼zyon, 10-14 gÃ¼n. Alternatif: Prokain PenG 2,4 mIU/gÃ¼n IM + Probenesit 500 mg 4Ã—1 Ã— 10-14 gÃ¼n. [CDC 2021]"},
  {q:"Non-treponemal testlerin (RPR/VDRL) treponemal testlerden temel farkÄ± nedir?",opts:["Daha yÃ¼ksek Ã¶zgÃ¼llÃ¼ÄŸe sahiptir","Kantitatif Ã¶lÃ§Ã¼lerek hastalÄ±k aktivitesini ve tedavi yanÄ±tÄ±nÄ± izlemede kullanÄ±lÄ±r","Ã–mÃ¼r boyu pozitif kalÄ±r","NÃ¶rosifiliz iÃ§in BOS'ta tercih edilir"],ans:1,fb:"RPR ve VDRL kantitatif Ã¶lÃ§Ã¼lÃ¼r; titre, aktif hastalÄ±kla korelasyon gÃ¶sterir. Tedaviyle titre dÃ¼ÅŸer, bu nedenle takipte kullanÄ±lÄ±r. Treponemal testler (FTA-ABS, TPHA) tedaviden baÄŸÄ±msÄ±z Ã¶mÃ¼r boyu pozitif kalabilir; aktivite takibinde kullanÄ±lmaz. [CDC 2021]"},
  {q:"Sekonder sifilizin patognomonik klinik bulgusu nedir?",opts:["YalnÄ±zca gÃ¶vdeyi tutan eritem","AÄŸrÄ±lÄ± genital Ã¼lser","AvuÃ§ iÃ§i ve ayak tabanÄ±nÄ± tutan makÃ¼lopapÃ¼ler dÃ¶kÃ¼ntÃ¼","Tek taraflÄ± fasiyel paralizi"],ans:2,fb:"AvuÃ§ iÃ§i (palmar) ve ayak tabanÄ± (plantar) tutulumu sekonder sifilizin son derece karakteristik bulgusudur. Bu bulgu diÄŸer dÃ¶kÃ¼ntÃ¼lÃ¼ hastalÄ±klarda nadiren gÃ¶rÃ¼lÃ¼r ve sifilizi ayÄ±rÄ±cÄ± tanÄ±da Ã¶n plana taÅŸÄ±r. [CDC 2021, Tuddenham 2022]"},
  {q:"Probenesit neden nÃ¶rosifiliz tedavisinde penisilinine eklenir?",opts:["Antibiyotik spektrumunu geniÅŸletir","Renal tÃ¼bÃ¼ler sekresyonu inhibe ederek penisilinin plazma/BOS konsantrasyonunu uzun sÃ¼re terapÃ¶tik dÃ¼zeyde tutar","BOS bariyerini delerek penisilinin SSS'ye geÃ§iÅŸini saÄŸlar","Jarisch-Herxheimer reaksiyonunu Ã¶nler"],ans:1,fb:"Probenesit renal organik asit sekresyon taÅŸÄ±yÄ±cÄ±larÄ±nÄ± inhibe ederek penisilinin atÄ±lÄ±mÄ±nÄ± yavaÅŸlatÄ±r; bÃ¶ylece plazma ve BOS'taki penisilin konsantrasyonu daha uzun sÃ¼re terapÃ¶tik seviyede kalÄ±r. Bu kombinasyon alternatif nÃ¶rosifiliz tedavisinde (Prokain PenG + Probenesit) kullanÄ±lÄ±r. [CDC 2021, Marra 2021]"},
  {q:"Sifiliz ve HIV ko-infeksiyonu hakkÄ±nda hangisi doÄŸrudur?",opts:["Sifiliz HIV riskini azaltÄ±r","Sifiliz tanÄ±sÄ±nda HIV araÅŸtÄ±rÄ±lmalÄ±; HIV pozitif hastada sifiliz taranmalÄ±dÄ±r â€” primer/sekonder sifiliz HIV edinme riskini ~18 kat artÄ±rÄ±r","HIV pozitif hastalarda sifiliz tedavisi farklÄ± antibiyotiklerle yapÄ±lmalÄ±dÄ±r","Bu iki enfeksiyon aynÄ± anda bulunmaz"],ans:1,fb:"CDC 2021 kÄ±lavuzuna gÃ¶re sifiliz ve HIV birlikte araÅŸtÄ±rÄ±lmalÄ±dÄ±r. Primer/sekonder sifiliz geÃ§irmek 1 yÄ±l iÃ§inde HIV edinme riskini yaklaÅŸÄ±k 18 kat artÄ±rÄ±r. HIV pozitif hastalarda sifiliz tedavi rejimleri aynÄ±dÄ±r; ancak serologic takip daha sÄ±k yapÄ±lÄ±r. [CDC 2021]"},
  {q:"Gebelikte penisilin alerjisi olan bir hastada sifiliz saptandÄ±. DoÄŸru yaklaÅŸÄ±m nedir?",opts:["Doksisiklin 100 mg 2Ã—1 Ã— 14 gÃ¼n ver","Sefalosporin ile tedavi et","Penisilin desensitizasyonu uygulayarak benzatin penisilin G ile tedavi et","Tedavi doÄŸum sonrasÄ±na bÄ±rak"],ans:2,fb:"Gebelikte doksisiklin kontrendikedir; sefalosporinlerin konjenital sifilizi Ã¶nlemedeki etkinliÄŸi kanÄ±tlanmamÄ±ÅŸtÄ±r. Bu nedenle penisilin alerjisi olsa bile desensitizasyon protokolÃ¼ uygulanarak penisilin G ile tedavi mutlaka yapÄ±lmalÄ±dÄ±r. Tedavinin ertelenmesi kabul edilemez. [CDC 2021]"}
];

let cUser='',qIdx=0,qCorr=0,qWrong=0,qAns=false;

// STORAGE
async function sGet(k){try{const r=await window.storage.get(k);return r?JSON.parse(r.value):null}catch{return null}}
async function sSet(k,v){try{await window.storage.set(k,JSON.stringify(v))}catch{}}

// LOGIN
document.getElementById('loginBtn').addEventListener('click',doLogin);
document.getElementById('loginName').addEventListener('keydown',e=>{if(e.key==='Enter')doLogin()});
function doLogin(){
  const nm=document.getElementById('loginName').value.trim();
  if(!nm){document.getElementById('loginName').focus();return}
  cUser=nm;
  const ls=document.getElementById('loginScreen');
  ls.style.opacity='0';
  setTimeout(()=>{ls.style.display='none';document.getElementById('app').style.display='block'},500);
  document.getElementById('topbarUser').textContent=nm;
  initQuiz();
  renderHistory();
}
document.getElementById('logoutBtn').addEventListener('click',()=>{
  document.getElementById('app').style.display='none';
  const ls=document.getElementById('loginScreen');
  ls.style.display='flex';ls.style.opacity='1';
  document.getElementById('loginName').value='';
});

// SECTION NAV
function goSection(id){
  document.querySelectorAll('.sec-tab').forEach(b=>b.classList.remove('active'));
  const tab=document.querySelector(`[data-sec="${id}"]`);
  if(tab){tab.classList.add('active');document.getElementById('topProgress').style.width=(tab.dataset.prog||'0')+'%'}
  document.querySelectorAll('.sec-page').forEach(p=>p.classList.remove('active'));
  const page=document.getElementById(id);
  if(page){page.classList.add('active')}
  if(id==='sq')initQuiz();
  if(id==='sh')renderHistory();
  window.scrollTo({top:0,behavior:'smooth'});
  // animate charts when visible
  setTimeout(animateCharts,300);
}

document.querySelectorAll('.sec-tab').forEach(btn=>{
  btn.addEventListener('click',()=>goSection(btn.dataset.sec));
});

// ACCORDION
document.querySelectorAll('.accord-head').forEach(h=>{
  h.addEventListener('click',()=>h.parentElement.classList.toggle('open'));
});

// TTS
let ttsOn=false;
document.getElementById('ttsBtn').addEventListener('click',()=>{
  if(!('speechSynthesis' in window))return;
  if(ttsOn){window.speechSynthesis.cancel();ttsOn=false;document.getElementById('ttsBtn').textContent='ğŸ”Š Sesli Oku';document.getElementById('ttsBtn').classList.remove('speaking');return}
  const pg=document.querySelector('.sec-page.active');
  if(!pg)return;
  let txt='';
  pg.querySelectorAll('p,.page-intro,.info-box,.card-desc,.accord-body,td,.algo-text,.rx-detail').forEach(el=>{txt+=el.innerText+' '});
  txt=txt.replace(/\s+/g,' ').trim();
  if(!txt)return;
  const u=new SpeechSynthesisUtterance(txt);
  u.lang='tr-TR';u.rate=0.95;
  u.onend=()=>{ttsOn=false;document.getElementById('ttsBtn').textContent='ğŸ”Š Sesli Oku';document.getElementById('ttsBtn').classList.remove('speaking')};
  ttsOn=true;
  document.getElementById('ttsBtn').textContent='â¹ Durdur';
  document.getElementById('ttsBtn').classList.add('speaking');
  window.speechSynthesis.speak(u);
});

// BAR CHART ANIMATION
function animateCharts(){
  document.querySelectorAll('.bar-fill[data-h]').forEach(bar=>{
    if(bar.style.height==='0px'||bar.style.height==='0'){
      setTimeout(()=>{bar.style.height=bar.dataset.h+'px';bar.style.transition='height 1.2s cubic-bezier(.4,0,.2,1)'},100);
    }
  });
}
setTimeout(animateCharts,400);

// QUIZ
function initQuiz(){
  qIdx=0;qCorr=0;qWrong=0;qAns=false;
  document.getElementById('qCorrect').textContent='0';
  document.getElementById('qWrong').textContent='0';
  document.getElementById('quizMain').style.display='block';
  document.getElementById('quizResult').style.display='none';
  document.getElementById('ringFill').style.strokeDashoffset='472';
  renderQ();
}
function renderQ(){
  qAns=false;
  const q=QUESTIONS[qIdx];
  document.getElementById('qProgLabel').textContent=`Soru ${qIdx+1} / ${QUESTIONS.length}`;
  document.getElementById('qText').textContent=q.q;
  document.getElementById('qFb').className='quiz-fb';
  document.getElementById('qFb').textContent='';
  document.getElementById('btnNext').disabled=true;
  document.getElementById('btnNext').textContent=qIdx===QUESTIONS.length-1?'SonuÃ§larÄ± GÃ¶r':'Sonraki â†’';
  const opts=document.getElementById('qOpts');
  opts.innerHTML='';
  const keys=['A','B','C','D'];
  q.opts.forEach((opt,i)=>{
    const btn=document.createElement('button');
    btn.className='quiz-opt';
    btn.innerHTML=`<span class="opt-key">${keys[i]}</span><span>${opt}</span>`;
    btn.addEventListener('click',()=>selectOpt(i));
    opts.appendChild(btn);
  });
}
function selectOpt(idx){
  if(qAns)return;
  qAns=true;
  const q=QUESTIONS[qIdx];
  const btns=document.querySelectorAll('.quiz-opt');
  btns.forEach(b=>b.setAttribute('disabled',''));
  const fb=document.getElementById('qFb');
  if(idx===q.ans){
    btns[idx].classList.add('correct');qCorr++;
    document.getElementById('qCorrect').textContent=qCorr;
    fb.textContent='âœ… DoÄŸru! '+q.fb;fb.className='quiz-fb show ok';
  }else{
    btns[idx].classList.add('wrong');btns[q.ans].classList.add('correct');qWrong++;
    document.getElementById('qWrong').textContent=qWrong;
    fb.textContent='âŒ YanlÄ±ÅŸ. '+q.fb;fb.className='quiz-fb show ko';
  }
  document.getElementById('btnNext').disabled=false;
}
document.getElementById('btnNext').addEventListener('click',()=>{
  qIdx++;if(qIdx>=QUESTIONS.length){showResult();return}renderQ();
});
async function showResult(){
  document.getElementById('quizMain').style.display='none';
  document.getElementById('quizResult').style.display='block';
  const pct=Math.round((qCorr/QUESTIONS.length)*100);
  document.getElementById('rPct').textContent=pct+'%';
  document.getElementById('rCorrect').textContent=qCorr;
  document.getElementById('rWrong').textContent=qWrong;
  let t,d;
  if(pct>=90){t='ğŸ† MÃ¼kemmel!';d='CDC 2021 ve gÃ¼ncel WHO verilerini Ã§ok iyi Ã¶zÃ¼msediniz. Klinik pratikte gÃ¼venle uygulanabilecek bir kavrayÄ±ÅŸa sahipsiniz.'}
  else if(pct>=70){t='ğŸ“ˆ Ä°yi Ä°lerleme!';d='Temel kavramlarÄ± kavramÄ±ÅŸsÄ±nÄ±z. TanÄ± algoritmasÄ±, tedavi rejimleri ve gÃ¼ncel epidemiyolojiyi gÃ¶zden geÃ§irin.'}
  else if(pct>=50){t='ğŸ“š Tekrar Ã–nerilir';d='Konuya hÃ¢kimiyetiniz geliÅŸiyor. Ã–zellikle serolojik testler ve CDC 2021 tedavi rehberine odaklanÄ±n.'}
  else{t='ğŸ”„ ModÃ¼lÃ¼ BaÅŸtan Ä°nceleyin';d='Her bÃ¶lÃ¼mÃ¼ referanslarÄ±yla birlikte tekrar okuyun, ardÄ±ndan quizi yeniden deneyin.'}
  document.getElementById('rTitle').textContent=t;
  document.getElementById('rDesc').textContent=d;
  setTimeout(()=>{document.getElementById('ringFill').style.strokeDashoffset=472-(472*pct/100)},300);
  const k=`sifiliz2_${cUser}`;
  const ex=await sGet(k)||[];
  ex.unshift({pct,correct:qCorr,wrong:qWrong,date:new Date().toLocaleString('tr-TR')});
  if(ex.length>20)ex.pop();
  await sSet(k,ex);
}
document.getElementById('btnRetry').addEventListener('click',()=>{initQuiz()});
document.getElementById('btnReview').addEventListener('click',()=>{goSection('s1')});

// HISTORY
async function renderHistory(){
  const el=document.getElementById('histList');
  if(!cUser){el.innerHTML='<div class="empty-hist">GiriÅŸ yapÄ±nÄ±z.</div>';return}
  const scores=await sGet(`sifiliz2_${cUser}`);
  if(!scores||!scores.length){el.innerHTML='<div class="empty-hist">HenÃ¼z quiz tamamlanmamÄ±ÅŸ.</div>';return}
  const medals=['ğŸ¥‡','ğŸ¥ˆ','ğŸ¥‰'];
  el.innerHTML=scores.map((s,i)=>`
    <div class="hist-item">
      <span class="hist-rank">#${i+1}</span>
      <span class="hist-score" style="color:${s.pct>=70?'var(--green)':s.pct>=50?'var(--amber)':'var(--red)'}">${s.pct}%</span>
      <div class="hist-meta"><div class="hist-date">${s.date}</div><div class="hist-correct">DoÄŸru: ${s.correct} / YanlÄ±ÅŸ: ${s.wrong}</div></div>
      <span class="hist-medal">${medals[i]||'ğŸ“‹'}</span>
    </div>`).join('');
}
</script>
</body>
</html>
